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SUMMARY 
The dysregulation of [Ca2+]i and [Na
+]i homeostasis is involved in 
neuronal and glial response occurring in several neurodegenerative 
diseases, including Multiple Sclerosis. The Na+/Ca2+ exchanger can be 
considered a key player in modulating the [Ca2+]i and [Na
+]i 
homeostasis following the injury. Recent evidence point out to the 
isoform NCX3 of the Na+/Ca2+ exchanger as a new potential therapeutic 
target for neuroprotection. The aim of the present study was to establish 
the role played by NCX3 in a murine model of Multiple Sclerosis. The 
experimental model used in these studies was the Experimental 
Autoimmune Encephalomyelitis (EAE). Biochemical analysis performed 
on spinal cord tissue homogenates revealed that NCX3 protein levels 
were progressively up-regulated during EAE progression; this effect 
was more significant at EAE chronic stage. In addition, quantitative 
confocal double immunofluorescence experiments showed that the co-
expression of NCX3 with both the myelin marker myelin basic protein 
(MBP) and the axonal marker neurofilament 200 (NF200) was 
significantly down-regulated at peak and chronic stages of EAE 
disease. By contrast, quantification of colocalization studies revealed 
that the co-expression of NCX3 with the oligodendrocyte lineage 
markers, the membrane chondroitin sulfate proteoglycan NG2, the 
Galactocebroside (GalC), and the 2‟-3‟-cyclic nucleotide-3‟-
phosphodiesterase (CNPase) was up-regulated during EAE 
progression. Interestingly, this up-regulation was more significant at 
EAE chronic stage. These early results suggested that NCX3 isoform 
might be involved in neuroprotective responses mediated by 
oligodendrocytes during the EAE recovery phase. The importance of 
the NCX3 isoform in oligodendroglial responses following EAE insult 
was supported by several findings: 1) at chronic stage of EAE disease, 
NCX3 knockout (ncx3-/-) mice displayed a reduced number of NG2 and 
CNPase positive cells when compared to NCX3 congenic wild type 
(ncx3+/+) mice; 2) NCX3 knockout (ncx3-/-) mice showed an earlier 
onset of symptoms and an increased susceptibility to the EAE disease 
when compared to NCX3 congenic wild type (ncx3+/+) mice. In 
conclusion, our findings suggested that NCX3 exchanger, by 
modulating [Na+]i and [Ca
2+]i homeostasis might play an important role 
in controlling oligodendrocyte response after a demyelinating insult. 
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I. INTRODUCTION 
 
1. The Na+/Ca2+ Exchanger (NCX) 
 
1.1 The Na+/Ca2+ Exchanger Molecule: an overview 
The Na+/Ca2+ exchanger is a transporter catalyzing the countertransport 
of three Na+ for one Ca2+ and is present in the plasma membrane of 
most cells (Philipson and Nicoll, 2000). NCX can mediate Ca2+ and Na+ 
fluxes across the synaptic plasma membrane in a bidirectional way 
(Blaustein and Lederer, 1999; Philipson and Nicoll, 2000). The Na+/Ca2+ 
exchanger was discovered and characterized in the late 1960s, when 
Baker et al. in the UK (Baker and Blaustein, 1968; Baker et al., 1969), 
Reuter and Seitz in Germany and Switzerland (Reuter and Seitz, 1968), 
and Martin and De Luca in the United States (Martin and De Luca, 
1969) realized the presence of a countertransport mechanism that 
exchanged Na+ and Ca2+ ions across the plasma membrane of different 
excitable and non excitable cells. However, the most crucial 
advancement in NCX research was made in 1988 (Philipson et al., 
1988) and 1990 (Nicoll et al., 1990), when Philipson and his colleagues 
purified and cloned the first isoform of this antiporter: NCX1. 
Remarkably, four years later, the same group of investigators cloned 
NCX2 (Li et al.,1994) and NCX3 (Nicoll et al., 1996b), two isoforms 
selectively expressed in the brain (Lee et al., 1994) and in the skeletal 
muscle (Nicoll et al., 1996b). Finally, in 1999, Philipson proposed a new 
topological model of the NCX1 exchanger (Nicoll et al., 1999).  
In the last two decades, there has been a growing interest in unraveling 
the role that the Na+/Ca2+ exchanger plays in the function and 
regulation of several cellular activities. Biochemistry, molecular biology, 
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electrophysiology, genetically modified mice, and molecular 
pharmacology have helped to delve deeper and more successfully into 
the physiological and pathophysiological role of this exchanger 
(Annunziato et al., 2004; Philipson et al., 2002). 
 
1.2 Molecular Biology of the Na+/Ca2+ Exchanger 
Three dominant genes coding for the three different NCX1 (Nicoll et 
al.,1990), NCX2 (Li et al., 1994), and NCX3 (Nicoll et al., 1996a) 
proteins have been identified in mammals. The ncx1 gene displays an 
ubiquitous expression, whereas NCX2 and NCX3 gene products 
have been found exclusively in neuronal and skeletal muscle tissues 
(Lee et al.,1994).These three genes appear to be dispersed, since 
NCX1, NCX2, and NCX3 have been mapped in mouse chromosomes 
17, 7, and 12, respectively (Nicoll et al.,1996b). NCX1 is composed of 
938 amino acids having a theoretical molecular mass of 120 kDa. NCX2 
and NCX3 gene products consist of 921 and 927 amino acids and are 
characterized by molecular masses of 102 and 105 KDa, respectively.  
All three NCX gene products share the same membrane topology. On 
the structural point of view, NCX is composed by nine transmembrane 
segments (Nicoll et al.,1999) that can be divided into an N-terminal 
hydrophobic domain, composed of the first five TMS (1–5), and into a 
C-terminal hydrophobic domain, composed of the last four TMS (6–9) 
.The amino terminus domain  is located in the extracellular space, 
whereas the carboxyl terminus domain is located intracellularly. These 
two hydrophobic domains are important for the binding and the 
transport of ions. The N-terminal hydrophobic domain (TMS 1–5) is 
separated from the C-terminal hydrophobic domain (TMS 6–9) through 
a large hydrophilic intracellular loop of 550 amino acids, named the f 
loop (Nicoll et al. 1999). Although the f loop is not implicated in Na+ and 
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Ca2+ translocation, it is responsible for the regulation of NCX activity 
elicited by several cytoplasmic messengers and 
transductional mechanisms, such as H+, Ca2+, and Na+ ions, nitric oxide 
(NO), phosphatidylinositol 4,5 bisphosphate (PIP2), protein kinase C 
(PKC), protein kinase A (PKA), phosphoarginine (PA), and ATP. In the 
center of the f loop, a region of approximately 130 amino acids in length 
(371–508 amino acids) has been reported to exert a Ca2+ regulatory 
function. This region is characterized by a pair of three aspartyl 
residues and by a group of four cysteines (Nicoll et al., 1999; Qiu et al., 
2001). At the N-terminal end of the f loop near the membrane lipid 
interface, an autoinhibitory domain, rich in both basic and hydrophobic 
residues and consisting of a 20-amino acid sequence (219–238), 
named exchange inhibitory peptide (XIP) (Matsuoka et al., 1997), has 
been identified. The f loop is also characterized by alternative splicing 
sites named β1-repeat and β2-repeat. These β-repeats are 
characterized by similar regions comprising 60 to 70 amino acids for 
which no functional role has yet been proposed (Hilgemann, 1990). The 
NCX protein amino acid sequence found between TMS 2 and TMS 3 is 
called α-1 repeat, whereas the one found between TMS 7 and TMS 8 is 
named α-2 repeat. Both regions, α-1 and α-2 repeats, are located on 
the opposite site of the membrane and include two segments composed 
of 12 and 9 highly conserved residues separated by a nonconserved 
segment of 18 to 20 amino acids (Nicoll et al., 2002). Since the putative 
α-helices of the α-repeats are amphipathic, the hydrophilic faces of 
these helices may form a portion of the ion translocation pathway (Nicoll 
et al., 1996a) (Fig. 1). 
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1.3 Functional Activity of NCX in Neurophysiological Conditions  
The regulation of intracellular concentrations of Ca2+ and Na+ ions in 
excitable cells is a relevant physiological phenomenon that maintains 
cellular homeostasis. In fact, although cytosolic Ca2+ ions play a key 
role in signaling at the cytosolic and nuclear levels (Choi, 1988), Na+ 
ions play a major role in regulating cellular osmolarity, in inducing action 
potential, and in transduction signaling (Yu et al., 1997). Indeed, the 
Na+/Ca2+ exchanger, in parallel with selective ion channels and ATP-
dependent pumps, maintains the physiological cytosolic concentrations 
of these ions (Blaustein and Lederer, 1999). The Na+/Ca2+ exchanger 
Figure 1. Topological model of the Na
+
/Ca
2+
 exchanger (NCX) protein. NCX is 
composed by nine transmembrane segments that can be divided into an N-terminal 
hydrophobic domain, composed of the first five TMS (1-5), and into a C-terminal 
hydrophobic domain, composed of the last four TMS (6-9). The N-terminal hydrophobic 
domain (TMS 1–5) is separated from the C-terminal hydrophobic domain (TMS 6–9) through 
a large hydrophilic intracellular loop of 550 amino acids, named the f loop. The conserved 
α1- and α2-repeat regions which span TMS 2 and 3, and TMS 7 and 8 are highlighted.  
Adapted from Iwamoto et al., Mol Pharmacol, 2004 
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protein is involved in different neurophysiological conditions. In 
particular, in the Central Nervous System (CNS), it plays a fundamental 
role in controlling changes in the intracellular concentrations of  Na+ and 
Ca2+ ions that occur in physiologic conditions such as neurotransmitter 
release, cell migration and differentiation, gene expression (Annunziato 
et al., 2004). The Na+/Ca2+ exchanger can mediate Ca2+ and Na+ fluxes 
across the synaptic plasma membrane in a bidirectional way (Blaustein 
and Lederer, 1999; Philipson and Nicoll, 2000). The stoichiometry of 
NCX is generally accepted to be three Na+ ions/one Ca2+ ion. When 
intracellular Ca2+ concentrations ([Ca2+]i) rise and the cells require the 
return to resting levels, this exchanger transport mechanism couples 
the uphill extrusion of Ca2+ ions to the entry of Na+ ions into the cells 
down their electrochemical gradient. This mode of operation, defined as 
forward mode or Ca2+ efflux or, more correctly, Ca2+-exit mechanism, 
keeps the 104-fold difference in [Ca2+]i across the cell membrane. In 
physiological as well in several pathophysiological conditions, when the 
intracellular Na+ concentrations ([Na+]i) rise or membrane depolarization 
occurs, thus reducing the transmembrane Na+ electrochemical gradient, 
NCX reverses its mode of operation and mediates the extrusion of Na+ 
and the entry of Ca2+ ions. This mode of operation is defined as reverse 
mode or Ca2+-entry mechanism. The mode of operation of the antiporter 
depends on (1) the transmembrane Na+ gradient, (2) the 
transmembrane Ca2+ gradient, and (3) the membrane potential.  
The Na+/Ca2+ exchanger becomes the dominant Ca2+ extrusion 
mechanism when [Ca2+]i is higher than 500 nM, as it happens when a 
train of action potentials reaches the nerve terminals. It has been 
calculated that for these [Ca2+]i values (500 nM), more than 60% of Ca
2+ 
extrusion is mediated by Na+/Ca2+ exchanger families. In such 
physiological conditions, NCX activation is consistent with its low-affinity 
and high-capacity function. In contrast, in resting conditions or after a 
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single action potential, when [Ca2+]i slightly increases, requiring, 
therefore, a more subtle control, the high-affinity and low-capacity 
pump, plasma membrane Ca2+ ATPase, assumes a predominant 
function, thus making the involvement of NCX less relevant (Blaustein 
and Lederer, 1999). 
Evidence has shown that NCX can modulate not only the synthesis and 
the release of neurotransmitters in the central and peripheral nervous 
system but also the release of anterior pituitary hormones (Taglialatela 
et al.,1988a,b; Di Renzo et al., 1995). It has been shown that NCX is 
also involved in the cellular events triggered by the activation of G-
protein-coupled neurotransmitter receptors. Thus, it has been 
demonstrated that the serotonin-induced increase of the firing rate of 
histaminergic tuberomammilar neurons is weakened by NCX inhibitors 
(Eriksson et al., 2001a,b). Interestingly, the serotonin receptor 5-HT2C, 
which mediates this effect on histaminergic tuberomammillar neurons, 
is also co-expressed with NCX1 (Sergeeva et al., 2003). Moreover, in 
the same histaminergic neurons, NCX activity plays a relevant role in 
orexin-induced depolarization (Eriksson et al., 2001b). Therefore NCX 
is a major player in the regulation of physiological responses to 
increases of [Ca2+]i and [Na
+]i (Annunziato et al., 2004; Philipson and 
Nicoll 2000). 
 
1.4 Genetically Modified-Mice for different NCX Isoforms  
In the last three decades an increasing number of compounds inhibiting 
NCX have been synthesized in order to identify the physiological role 
played by NCX isoforms, NCX1, NCX2 and NCX3; however, at present 
no isoform-specific compounds have been yet identified (Annunziato et 
al., 2004). Moreover, these drugs, despite their potency, possess some 
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non specific actions against several ion channels and receptors (Reuter 
et al., 2002a) as a result it is difficult to discriminate the direct effects of 
NCX inhibition from the inhibition/activation of channel receptors or 
enzymes. Thus, the use of these non specific inhibitors to characterize 
the role of each NCX isoform should be interpreted with caution (Reuter 
et al., 2002a). Because of the limitations of the currently available 
pharmacological tools acting on NCX, transgenic mice for NCX1, NCX2 
and NCX3 were generated in order to identify the role of each antiporter 
isoform under physiological and pathophysiological conditions. In 2000 
four independent laboratories generated knockout mice for NCX1. 
Unfortunately, these mice die in utero at 9.5 days poistcoitum because 
the lack of cardial NCX1 in homozygote state causes the absence of a 
spontaneous heart beat (Cho et al., 2000; Koushik et al., 2001; Reuter 
et al., 2002b; Wakimoto et al., 2000). Later, Henderson et al. (2004) 
showed how to over-come this limitation by using the Cre-loxP 
technique in the heart demonstrating that NCX1 gene ablation in adult 
mice is compatible with life. As far as the other isoform NCX2 is 
concerned, its knocking out is compatible with life and survival until 
adulthood (Jeon et al., 2003). Also NCX3 knockout (ncx3-/-) mice 
survive until the adulthood. In particular, ncx3 -/- mice were fertile, they 
appeared grossly normal and showed normal body weight (Sokolow et 
al., 2004). The use of genetic-modified mice for NCX1, NCX2 and 
NCX3 represents a fruitful strategy to characterize the physiological role 
exerted by NCX in CNS and to identify the isoforms of the antiporter as 
potential molecular targets for therapeutic intervention. 
 
1.5 Distribution of Na+/Ca2+ Exchanger Isoforms 
The distribution of the three NCX isoforms in the mammalian brain gave 
useful insights into the physiological and pathophysiological role played 
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by the different NCX isoforms in the regulation of neuronal function. In 
fact, NCX1, NCX2 and NCX3 are highly and selectively expressed in 
the mammalian brain, suggesting that NCX proteins may play a 
differential role in the regulation of brain cell functions. Indeed, NCX1 
and NCX3 have several splicing variants that appear to be selectively 
expressed in different regions and cellular populations of the brain 
(Quednau BD et al., 1997; Yu SP and Choi DW, 1997). The NCX1 gene 
displays an ubiquitous expression and therefore is present in several 
tissues, including brain, heart, skeletal muscle, smooth muscle, kidney, 
eye, secretory, and blood cells whereas NCX2 and NCX3 gene 
products have been found exclusively in neuronal and skeletal muscle  
tissues (Lytton J, 2002). In the cerebral cortex, NCX1 is intensively 
expressed in neurons of layer III and V within the molecular layer of the 
cerebral motor cortex. This area, which contains the terminal dendritic 
field of the pyramidal cells, displays a more intense NCX1 
immunoreactivity than that of NCX2. In contrast, the somatosensory 
cortical area seems to express preferentially NCX2 transcripts. Such 
anatomical distribution reveals that the upper neurons of the motor 
system and the terminal neurons of the somatosensory system 
preferentially express distinct NCX isoforms (Canitano et al., 2002; 
Papa et al., 2003). Within the hippocampus, the transcripts of the three 
NCX isoforms display an intense labeling within selective neuronal 
populations. In particular, high levels of the three NCX genes have been 
detected in the granular cell layers of the dentate gyrus and in the 
pyramidal cells of CA1, CA2, CA3, and CA4 subfields (Papa et al., 
2003). The three NCX protein isoforms also display high levels of 
expression within the hippocampus. Thus, in the oriens and radiatum 
layers of the CA1 subfield, NCX3 protein is more intense than NCX1 
and NCX2. NCX1 protein expression is particularly intense in the 
granule cell layer and in the hilus of the dentate gyrus, which constitutes 
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the terminal field of the perforant pathway, the major excitatory input to 
the hippocampus originating from the enthorinal cortex. In the CA3 
area, the expression of NCX1 and NCX3 genes within the mossy fibers 
projecting from the granule cells located in the dentate gyrus are more 
intense than those of NCX2. This peculiar distribution suggests that 
distinct NCX isoforms may play a crucial role in controlling the 
intracellular Na+ and Ca2+ homeostasis of the major afferent, intrinsic, 
and efferent hippocampal projections. Such circuitries are crucial for the 
synaptic plasticity phenomena, such as those involved in long-term 
potentiation (LTP) and long-term depression (Madison et al.,1991). 
NCX isoforms are also expressed in crucial areas of the extrapyramidal 
control of motor coordination. In fact, NCX1 mRNA can be detected in 
the substantia nigra pars compacta, in which dopaminergic cell bodies 
are localized; the NCX1 protein isoform is present in the striatum, in 
which the terminal projection fields of dopaminergic nigrostriatal 
neurons are found. Interestingly, both the transcripts and the proteins, 
encoded by the three NCX genes, are abundantly expressed in the 
nucleus accumbens (Canitano et al., 2002; Papa et al.,2003). 
 
1.6 The Na+/Ca2+ Exchanger in Glial Cells  
The Na+/Ca2+ exchanger protein is present in both neurons and glia, 
and may play a relevant function in different neurophysiological 
conditions. In glial cells the Na+/Ca2+ exchanger is significantly 
expressed (Finkbeiner, 1993; Goldman et al., 1994; Holgado and 
Beauge, 1996; Takuma et al., 1994) but its precise role has not yet 
been determined. Glial cells constitute the large majority of cells in the 
nervous system. They account for about 90% of all cells in the human 
brain. During recent years a large number of studies have critically 
changed the image of glia from a silent and passive supportive cells to 
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important partner of neurons in brain functions. Glial cells are involved 
in almost every type of neurodegenerative diseases. Alteration of 
intracellular ionic homeostasis in response to CNS injury plays a crucial 
role in inducing and maintaining glial responses in the injured brain. 
Reactions of glial cells which include the reaction of astroglia, such as 
reactive astrogliosis, microglia, such as activation of microglia, and 
oligodendroglia, such as Wallerian degeneration and demyelination are 
of critical importance for the progress of neural pathology (Annunziato 
et al., 2013). 
 
1.6.1 NCX in Microglia  
All three NCX exchangers, NCX1, NCX2 and NCX3 are expressed in 
microglial cells, but NCX1 is the most highly expressed (Nagano T et 
al., 2004; Boscia et al., 2009). NCX activity in microglia was first 
recorded by Matsuda et al. (2001) who observed a Na+-dependent 
45Ca2+ uptake inhibited by the NCX inhibitor SEA0400. Functional 
studies indicated that NCX1 in microglia plays a key role in the 
response to IFN-γ and NO, two cell products implicated in several CNS 
pathologies including stroke. Treatment of microglial cells with 
interferon-γ caused a biphasic increase in NCX activity. The delayed 
increase in NCX activity was accompanied by increases in mRNA and 
protein levels of all NCX isoforms (Nagano T et al., 2005). 
Pharmacological studies show that protein kinase C and tyrosine kinase 
inhibitors prevent the transient increase in NCX activity induced by IFN-
γ, whereas a mitogen-activated protein (MAP) kinase/extracellular 
signal regulated protein kinase (ERK) is involved in the delayed 
increase in NCX activity (Nagano et al., 2004). Furthermore, using the 
specific NCX inhibitor SEA0400, Nagano et al. (2005) showed that NO 
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activates NCX and that NCX is involved in NO-induced depletion of 
Ca2+ in the endoplasmic reticulum (ER), leading to ER stress. The 
responses of NCX to interferon-γ and NO implies that Ca2+ uptake via 
NCX operating in reverse mode may play a role for microglial activation 
under pathological conditions. Recently, a prominent role of NCX in 
microglial migration have been suggested (Ifuku et al., 2007). In fact, 
Ca2+ influx via reverse-mode activity of the Na+/Ca2+ exchanger is 
prerequisite for bradykinin and B1 receptor agonist-induced microglial 
motility. The knocking out of NCX1 in the heterozygous state impairs 
bradykinin-induced chemotaxis or migration in microglia. The relevance 
of NCX1 function in microglia are further supported by the findings that 
ncx1-/- embryos have no detectable microglia in the brain when 
compared to ncx1+/+ control littermates (Ginhoux et al., 2010). The 
crucial role of NCX1 isoform in activated microglia under 
patophysiological conditions is becoming further evident. Phagocytosis 
and the ensuing NADPH-mediated respiratory burst are important 
aspects of microglial activation that require calcium influx. Inhibiting the 
reverse mode of the Na+/Ca2+ exchanger with KB-R7943, dose 
dependently reduced the phagocytosis-stimulated respiratory burst 
(Newell et al., 2007). In accordance with the role played by NCX in 
phagocytic microglia, it has been demonstrated that 3 and 7 days after 
pMCAO, NCX1 signal progressively increased in the Iba1-positive 
microglia invading the infarct core. In these cells, NCX1 expression was 
limited to the round phagocytic phenotype, which represents the final 
stage of microglia activation (Boscia et al., 2009).  
 
1.6.2 NCX in Astrocytes 
The Na+/Ca2+ exchanger is abundantly expressed in astrocytes 
(Finkbeiner, 1993; Goldman et al., 1994; Holgado and Beauge, 1996; 
12 
 
Takuma et al., 1994). In particular, NCX1 represents the most abundant 
NCX isoform expressed in astrocytes (He et al., 1998), where, when 
operating in the reverse mode, it can deliver Ca2+ to the cytosol 
(Kirischuk et al., 1997; Rojas et al., 2008). The most important role 
played by NCX1 in astrocytes is related to the regulation of 
gliotransmitter release (Zorec et al., 2012). Hence, mild depolarization 
of astrocytes cultured from adult rats forces NCX to operate in the 
reverse mode and generates cytosolic Ca2+ increases leading to 
release of glio-transmitters such as glutamate (Paluzzi et al., 2007; 
Reyes and Parpura, 2009). On the other hand, it should be underlined 
that since the gliotransmitter release is modulated by cytosolic Ca2+ 
levels in astrocytes, NCX1 is not the only protein involved in this 
process. In fact, mitochondria (Duchen et al., 2008), SERCA and Ca2+-
ATPase (Reyes et al., 2012), by regulating cytosolic Ca2+ levels, trigger 
exocytotic release of different gliotransmitters from astrocytes (Parpura 
and Zorec, 2010). 
 
1.6.3 NCX in Oligodendrocytes 
All three NCX isoforms have been detected in primary cultures of 
oligodendrocytes and oligodendrocyte precursor MO3.13 cell line 
(Quednau et al., 1997; Boscia et al., 2012). The staining of NCX1 in 
myelinated axons of the sciatic nerve, optic nerve and spinal cord, is 
similar being associated both with axons as well as oligodendrocyte cell 
bodies and their processes. The lack of NCX staining in some white 
matter regions, as NCX1 in the corpus callosum, raises the possibility 
that the localization of the three exchanger isoforms may be different 
within white matter tracts (Steffensen et al., 1997). NCX1 and NCX3 
isoforms are differently expressed in Oligodendrocyte Precursor Cells 
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(OPCs) and are divergently modulated during differentiation of OPCs 
into oligodendrocytes (Boscia et al., 2012). Indeed, whereas NCX1 
isoform decreases, NCX3 isoform is strongly increased during 
oligodendrocyte maturation. Expression and functional studies suggest 
that NCX1 represents the main contributor to NCX currents (INCX) 
recorded in OPCs. Tong et al. (2009) have shown that NCX1, but not 
NCX2, is highly expressed in OPCs and that pharmacological inhibition 
of NCX1 or its selective silencing with siRNA largely inhibits migration 
and GABA-induced Ca2+ signaling in cultured OPCs. NCX3 represents 
the main isoform expressed in mature oligodendrocytes and, 
consequently, the main contributor to INCX recorded in these cells. The 
importance of calcium signaling mediated by NCX3 exchanger during 
oligodendrocyte development and myelin formation is supported by 
several findings: 1) the knocking down of NCX3 expression and activity 
by siRNA strategy in OPC cultures prevented the up-regulation of the 
myelin proteins; 2) NCX3 overexpression induced the up-regulation of 
the two myelin markers CNPase and MBP; 3) NCX3 knockout mice 
exhibit hypomyelination that is accompanied by an augmented number 
of the OPC cells, and a reduction of spinal cord size (Boscia et al., 
2012). Previous studies have demonstrated a central role of NCX in 
anoxic and ischemic injury of both central and peripheral myelinated 
axons. Indeed, the reverse mode operation of NCX has been implicated 
in axonal damage during spinal cord anoxia (Li et al., 2000), stretch 
injury of axons (Wolf et al., 2001), and experimental allergic 
encephalomyelitis (Craner et al., 2004). In oligodendrocytes NCX1 and 
NCX3 are co-localized with the Na+-K+-2Cl- co-transporter (NKCC1). 
The reverse mode operation of NCX and NKCC1 has been also 
implicated in oligodendrocyte cell death induced by AMPA-mediated 
excitotoxicity. Activation of AMPA receptors leads to NKCC1 
phosphorylation that enhances NKCC1-mediated Na+ influx. The latter 
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triggers NCX in the reverse mode of operation with consequent Ca2+ 
overload that compromises mitochondrial function and cellular viability 
(Chen et al., 2007). 
 
1.7 Relevance of Na+/Ca2+ Exchanger Activity in 
Neurodegenerative Conditions 
The dysregulation of [Ca2+]i and [Na
+]i homeostasis is involved in 
neuronal and glial injury occurring in in vitro and in vivo models of 
several neurodegenerative diseases (Annunziato et al., 2004). The 
Na+/Ca2+ exchanger can be considered a major player in the regulation 
of neuropathophysiological responses following alterations in [Ca2+]i and 
[Na+]i (Annunziato et al., 2004; Philipson and Nicoll 2000). 
 
1.7.1 Hypoxia-Anoxia 
Cell calcium is thought to play a key role in mediating ischemic neuronal 
damage (Kristian and Siesjo, 1996), and thus it is critical to understand 
how it is regulated. Cytosolic Ca2+ is elevated during global ischemia 
(Erecinska and Silver, 1992; Nakamura et al., 1999) and during in vitro 
ischemia (deprivation of glucose and oxygen) in brain slices (Mitani et 
al., 1993), as well as in neuronal cell cultures that are exposed to 
mitochondrial and glycolytic inhibitors (Dubinsky and Rothman, 1991). 
Ischemia induces a large increase in glutamate release in brain tissue 
in vivo (Benveniste et al., 1984) and in vitro (Lobner and Lipton, 1990), 
and there is evidence of an NMDA component to the increase in 
cytosolic Ca2+ during global ischemia (Erecinska and Silver, 1992), 
during anoxia in cortical slices (Bickler and Hansen, 1994), and in 
organotypic hippocampal cultures (Velazquez et al., 1997). The 
Na+/Ca2+ exchanger represents a key mediator for maintaining 
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intracellular [Na+]i and [Ca
2+]i homeostasis in response to brain 
ischemia (Boscia et al., 2009). Nevertheless, the role played by NCX 
proteins in cell injury in different experimental models of cerebral 
ischemia remains controversial. In a cellular model of glial cells, C6 
glioma, the activation of  NCX, as Na+-efflux Ca2+-influx pathway, 
obtained by [Na+]e removal, reduces cell injury induced by chemical 
hypoxia. Such phenomenon suggests that the antiporter plays a 
protective role during this pathophysiological condition. Consistent with 
these results, the pharmacological inhibition of NCX activity worsens 
cell damage by increasing the intracellular concentration of Na+ ions 
(Amoroso et al., 1997). Furthermore, the stimulation of NCX activity by 
redox agents results in a protective effect (Amoroso et al., 2000). In 
addition, in cells singly and stably transfected with NCX3, this isoform 
contributes more significantly to the maintenance of [Ca2+]i homeostasis 
during experimental conditions mimicking ischemia, thereby preventing 
mitochondrial ΔΨ collapse and cell death (Secondo et al., 2007). 
Consistent with the protective function played by NCX, in cortical 
neurons exposed to oxygen and glucose deprivation, the nuclear factor 
kappa-B-dependent NCX1 up-regulation seems to play a fundamental 
role in Ca2+ refilling in the endoplasmic reticulum, thus helping neurons 
to prevent endoplasmic reticulum stress (Sirabella et al., 2009). 
Inconsistent with these results, in astrocytes, during the reoxygenation 
phase, the inhibition of the antiporter decreases cell toxicity (Matsuda et 
al., 1996, 2001), whereas NCX stimulators, such as NO donors, worsen 
the injury (Matsuda et al., 1996). Conflicting reports on the role played 
by NCX activity in glutamate-induced neuronal damage, an in vitro 
model mimicking cerebral ischemia, have been published (Andreeva et 
al., 1991; Kiedrowski et al., 1999; Schroder et al., 1999; Amoroso et al., 
1993). For instance, studies on cerebellar granule cells, as well as on 
glial cells (Amoroso et al., 2000), have reported that the inhibition of 
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NCX exacerbates delayed neuronal death elicited by glutamate 
(Andreeva et al., 1991). In contrast, in the same model, other 
investigators have demonstrated that Ca2+ influx, mediated via reverse 
mode of NCX operation, constitutes the dominant component of NMDA-
induced Ca2+ entry and excitotoxicity (Kiedrowski, 1999). The same 
mechanism, an Na+-mediated reversal of NCX activity, leads to the 
death of depolarized and glucose-deprived neurons (Czyz and 
Kiedrowski, 2002). In line with the latter hypothesis, it has been 
demonstrated that in rat hippocampal slices, the inhibition of NCX 
protects CA1 neurons against hypoxic-hypoglycemic injury (Schroder et 
al., 1999). In in vivo models, reproducing human cerebral ischemia 
through the occlusion of the middle cerebral artery, the inhibition of 
NCX, induced by selective inhibitors (Pignataro et al., 2004) or by the 
knockout of one of the NCX isoforms (NCX2) (Jeon et al., 2003a), 
aggravates brain infarct, whereas the activation of the antiporter with 
redox agents reduces the cerebral infarctual area (Pignataro et al., 
2004b). In addition, in in vivo experiments, the selective knocking down 
of NCX1 and NCX3, but not of NCX2, by antisense 
oligodeoxynucleotide strategy (Pignataro et al., 2004), or the disruption 
of the ncx3 gene, renders the brain more susceptible to the ischemic 
insult (Molinaro et al., 2008). At variance with these data, Matsuda et al. 
(2001) reported that the inhibition of NCX, induced by putative selective 
NCX inhibitors, such as KB-R7943 and SEA0400, reduces brain injury 
in the model of transient middle cerebral artery occlusion. However, KB-
R7943, besides blocking the antiporter, also produces a remarkable 
and prolonged hypothermic effect (Pignataro et al., 2004b) that exerts, 
by itself, a relevant neuroprotective action in cerebral ischemia. On the 
other hand, by inhibiting other cellular ionic transport mechanisms and 
receptors, such as NMDA receptors and L-type Ca2+ channels (Matsuda 
et al., 2001), the same drug may yield a neuroprotective effect (Lo et 
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al., 2003). In regard to the other putative NCX inhibitor, SEA0400, it 
should be underlined that Matsuda et al. (2001) used an animal model 
of cerebral ischemia in which the neuronal damage mainly occurred 
during the reperfusion period with a Ca2+ paradox-like injury 
accompanied by an exaggerated ROS production and apoptotic cell 
death (Matsuda et al., 2001). These data suggest that if NCX proteins 
are neuroprotective during ischemic injury, the major role is prevalently 
exerted by the NCX1 and NCX3 gene products. Taken togheter, at 
present, it is not clear whether the function of NCX exchangers mediate 
positive or negative effects after ischemic episodes. A new emerging 
concept is that NCX1, NCX2 and NCX3 may exert different roles during 
in vitro (Secondo et al. 2007) and in vivo (Annunziato et al 2004) anoxic 
conditions. Consistent with the idea of a differential function for the 
three NCX proteins, their pathophysiological implications may as well 
be distinct. The role played by NCX in those neurons and glial cells 
involved in cerebral ischemia should be differentiated according to the 
anatomical regions involved in the ischemic pathological process. In 
particular, it is conceivable that, since in the penumbral region ATPase 
activity is still preserved, NCX may likely operate in a forward mode. As 
a result, by extruding Ca2+ ions, the exchanger favors the entry of Na+ 
ions. Therefore, the inhibition of NCX in this area reduces the extrusion 
of Ca2+ ions, thus enhancing Ca2+-mediated cell injury. In contrast, in 
the ischemic core region, in which ATP levels are remarkably low and 
Na+/K+ ATPase activity is reduced, intracellular Na+ ions massively 
accumulate because of Na+/K+ ATPase failure. Hence, the intracellular 
Na+ loading promotes NCX to operate in the reverse mode as an Na+ 
efflux-Ca2+ influx pathway. In conclusion, the NCX pharmacological 
inhibition in this core region further worsens the necrotic lesion of the 
surviving glial and neuronal cells as the loading of intracellular Na+ 
increases (Pignataro et al., 2004b). 
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1.7.2 Aging 
The impairment of Ca2+ homeostasis in neuronal cells is considered to 
be the major triggering event that leads to the development of brain 
aging (Annunziato et al., 2002). Studies performed on the cerebro-
cortex nerve endings of aged rats have shown that the activity of NCX 
is markedly reduced in the forward and in the reverse mode of action 
(Michaelis et al., 1984; Canzoniero et al., 1992). NCX decline seems to 
be the consequence of a reduced affinity of the antiporter for Ca2+ ions 
(Michaelis et al., 1984).  
 
1.7.3 Alzheimer’s Disease 
A large bulk of studies have shown that the neurotoxicity exerted by the 
amyloid-β (A-β) protein is intimately related to intracellular Ca2+ 
concentrations. Indeed, the attenuation of [Ca2+]i increase by Ca
2+ 
channel blockers (Weiss et al., 1994), growth factors (Mattson et al., 
1993), and cytochalasins (Furukawa and Mattson, 1995) results in a 
reduction of neural damage induced by the A-β protein. It has recently 
been demonstrated that exposure to the A-β protein partially reduces 
Na+-dependent Ca2+ accumulation in plasma membrane vesicles 
deriving from the human frontal cortex of patients affected by 
Alzheimer‟s disease (Wu et al., 1997). These findings have suggested 
that A-β directly interacts with the hydrophobic surface of the NCX 
molecule, thus interfering with plasma membrane Ca2+ transport.  
Sokolow et al., 2011 demonstrated that high levels of synaptosomal 
Na+-Ca2+ exchangers (NCX1, NCX2, NCX3) co-localized with amyloid-
beta in human cerebral cortex affected by Alzheimer's disease. More 
recently, it has been shown that Aβ(1-42), through Ca2+-dependent 
calpain activation, generates a hyperfunctional form of NCX3 that, by 
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increasing Ca2+ content into ER, delays caspase-12 activation and thus 
neuronal death (Pannaccione et al., 2012). 
In addition, Atherton et al., 2014 demonstrated that calpain cleavage 
and inactivation of the sodium calcium exchanger-3 occur downstream 
of Aβ in Alzheimer's disease. 
 
1.7.4 Multiple Sclerosis 
Although demyelination and inflammation have classically been 
considered to be histopathological hallmarks of Multiple Sclerosis, 
axonal pathology in Multiple Sclerosis has been recognized for over a 
century (Charcot, 1868). It has recently been demonstrated that axonal 
degeneration contributes to the development of non-remitting 
neurological deficits and disability in Multiple Sclerosis, but the 
molecular mechanisms that underlie axonal loss in Multiple Sclerosis 
are not clearly understood.  
The precise role of the Na+/Ca2+ exchanger in axonal degeneration has 
not been resolved. Evidence suggesting that voltage-gated sodium 
channels and the Na+/Ca2+ exchanger might cooperate in triggering 
degeneration of white matter axons was provided by early studies that 
demonstrated that sodium channels can participate in the production of 
calcium-mediated axonal degeneration of axons within the anoxic optic 
nerve (Stys et al., 1992). Studies of white matter axonal injury have 
demonstrated  that voltage-gated sodium channels can provide a route 
for sodium influx into axons that triggers reverse operation of the NCX 
and subsequent influx of damaging levels of intra-axonal calcium. 
Several reports suggest that NCX plays a major role in mediating Ca2+-
induced white matter damage induced by anoxia or trauma. During 
these noxious stimuli, myelinated axons lose K+, whereas intra-axonal 
Na+ concentrations increase after Na+ entry, primarily through voltage-
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gated tetrodotoxin-sensitive channels. Hence, elevated axoplasmic Na+ 
and axolemmal depolarization promote a neurodetrimental Ca2+ 
overload mediated primarily by NCX operating in the reverse mode 
(Stys and Lopachin, 1998). In fact, drugs capable of inhibiting NCX 
activity, such as bepridil and amiloride derivatives, reduce white matter 
damage in different experimental models of axonal injury: rat optic 
nerve anoxia (Stys et al., 1990; Stys and Lopachin, 1998), spinal cord 
injury (Li et al., 2000), and stretch-injured axons (Wolf et al., 2001). 
More recently, a role of NCX and sodium channels in axonal 
degeneration in neuroinflammatory disorders has been suggested by 
the protective effect of low doses of the sodium channel blockers 
lidocaine and flecainide and tetrodotoxin (TTX) (Garthwaite et al., 2002) 
and the NCX blocker bepridil on axonal injury triggered by nitric oxide 
(NO). 
 In addition, Waxam and co-workers (Craner et al., 2004a) have shown 
that NCX co-localizes with Nav1.6 in the injured axons in the spinal cord 
of mice with EAE (Craner et al., 2004b). In particular, Craner et al. 
(2004) have demonstrated the up-regulated expression of Nav1.2 and 
Nav1.6 along extensive regions of demyelinated axons in EAE. 
Although the development of a diffuse distribution of Nav1.6 throughout 
long regions of demyelinated axons may facilitate restoration of action 
potential propagation (Bostock and Sears, 1976, 1978; Foster et al., 
1980; Black et al., 2002), ectopic expression of Nav1.6 along the axonal 
membrane might also have a deleterious effect on axons, especially if 
Nav1.6 and NCX are co-localized. Several lines of evidence suggest 
that Nav1.6 contributes to the persistent current that drives reverse NCX 
in injured axons in Multiple Sclerosis (Craner et al., 2004). The 
proposed mechanism involves massive sodium influx into axons that 
triggers reverse operation of the exchanger and subsequent influx of 
damaging levels of intra-axonal calcium that is associated with axonal 
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injury (Craner et al., 2004) (Fig. 2). Overall, these studies emphasize 
the relevance of NCX modulation in an attempt to prevent white matter 
degeneration in different models of axonal injury. 
 In Multiple Sclerosis, it is clear that neurodegenerative processes are 
linked to irreversible disability in later stages of the disease. In this 
regard, the role and contribution of calcium pumps and exchangers to 
Multiple Sclerosis pathology warrant further investigations. 
 
 
 
 
 
 
 
 
 
 
 
 
2. Multiple Sclerosis (MS) 
2.1 Introduction to MS 
Multiple Sclerosis has been known through past centuries as paraplegia 
(Murray, 2009). The depiction of “a remarkable lesion of the spinal cord 
accompanied with atrophy” by Robert Carswell in 1838 anticipated a 
more or less complete description of the pathological anatomy and 
clinical features of MS. Previously unrecognized, MS makes a fleeting 
appearance in the early 19th century before taking centre stage as 
clinical neurology began to flourish in the 1860s. By the beginning of the 
20th century, a disease only a few years earlier meriting individual case 
Figure 2. Proposed mechanism of axonal injury by means of co-expression of Nav1.6 
and NCX. The model suggests that Nav1.6 sodium channels are up-regulated (1) and 
expressed along some demyelinated axons, where they produce persistent sodium current 
(2). The persistent sodium current can drive reverse sodium/calcium exchange (3) and 
accumulation of intra-axonal calcium (4), triggering injurious secondary cascades and axonal 
injury. 
Adapted from Craner et al., PNAS , 2004 
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reports had become one of the most common reason for admission to a 
neurological ward. The first classical description of MS was made by 
Jean Martin Charcot (Charcot, 1868), who also gave this disease a 
name. It was also Charcot who, in 1877, realised the role of disrupted 
myelin in the pathogenesis of the disease. 
 MS is an autoimmune inflammatory demyelinating disease of the CNS, 
which culminates in progressive neurological deterioration. The ideas 
developed for the cause and pathogenesis of the disease are based on 
studies of epidemiology, genetics, pathology, immunology, and 
neurobiology. 
 
2.2 Epidemiology 
MS is the most common inflammatory demyelinating disease of the 
CNS and the most common disabling neurological disease afflicting 
young adults. The mean age of onset is approximately 30 years. Almost 
70% of patients manifest symptoms between ages 20 and 40. Disease 
onset rarely occurs prior to 10 or after 60 years of age. There is clear 
gender difference with females being more frequently affected than 
men. 
The worldwide incidence and prevalence of MS is highly variable with 
both genetic and geographical factors playing a role. The greatest 
incidence tends to be at the extremes of latitude in both Northern and 
Southern hemispheres. The disease is more common in subjects with 
Western European ancestry. In particular, Scotland and the Outer 
Hebrides are the regions with the highest recorded prevalence rates of 
up to 300 cases per 100.000. In England and Wales, prevalence rates 
have varied from 74 to 112 per 100.000. In contrast, there are ethnic 
groups that seem to be resistant to the disease despite inhabiting areas 
of relatively high prevalence rate such as Maoris in New Zealand, 
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Hutterites and the Natives in Western Canada. There is no clear 
explanation for the differences in worldwide distribution of MS. Genetic 
factors seem to be strongly associated. Environmental factors 
undoubtedly have strong impact on disease distribution and prevalence. 
This is supported by observations that migration from high-risk to low-
risk areas before puberty affords some protection from acquiring MS 
and numerous outbreaks or clusters of the disease have been 
described (Kondar et al., 2010). 
 
2.3 Aetiology  
The aetiology of MS remains elusive, as both genetic predisposition and 
environmental factors are indicated. Arguing the merits of one faction 
versus the other is unproductive. Each is clearly implicated, together 
with the cultural condition of age at which the interplay between genes 
and the environment occurs. 
The importance of genetic predisposition is evident from very high 
concordance of the disease occurrence between monozygotic twins, 
whereas the environmental factors are implicated by the existence of 
geographical areas with remarkable differences is MS prevalence. The 
general theory regards MS aetiology as an infection which presents the 
immune system with an antigen similar to CNS myelin. Numerous 
viruses that display homology to myelin components are implicated and 
proposed as the infective trigger, such as hepatitis B virus and the 
herpes viruses, Epstein-Barr virus, herpes simplex virus, and 
cytomegalovirus (CMV), as well as influenza viruses and 
papillomaviruses. The resulting antibodies eventually attack CNS 
myelin and cause demyelination. This theory, however, is very broad 
and imprecise, as MS can cover several aetiologically distinct diseases 
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with similar pathological endpoint and clinical features (Verkharatsky 
and Butt, 2013). 
 
2.4 Classification and Clinical Course  
Clinically, MS manifests itself as a neurological deficits that frequently 
exhibit a relapsing and remitting pattern and can resolve completely or 
leave residual deficits. The deficits can involve any part of the CNS 
alone or in combination. Somatosensory, pyramidal-motor and visual 
manifestations, the latter due either to inflammatory demyelination in 
the afferent visual pathways (optic neuritis) or in the efferent visual 
pathways are among the most common manifestations. In terms of the 
clinical course, there are several MS subtypes: relapsing-remitting MS 
(RRMS), secondary progressive (SPMS), primary progressive (PPMS) 
and progressive-relapsing MS (PRMS) (Lublin and Reingold,1996). 
The most common form of the disease is RRMS, which is observed in 
about 85% of all patients. RRMS is characterized by clearly defined 
disease relapses with full recovery or with sequelae and residual deficit 
upon recovery. Although RRMS is not classified as a progressive form 
of multiple sclerosis, residual deficits may occur after each 
exacerbation. 
At least half of all patients with RRMS will develop to secondary 
progressive multiple sclerosis (SPMS). This subform is characterize by 
disease progression with or without occasional relapses, minor 
remissions, and periods of stability. 
In contrast, PPMS is seen in far fewer patients (about 10%). It is 
characterized from the outset by the absence of acute attacks but 
demonstrates a worsening in disease severity. 
Progressive relapsing multiple sclerosis (PRMS) is the least common 
form of the disease, affecting about 5% of patients. From the outset it is 
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progressive, with or without full recovery, and progression is continuous 
between relapse periods (Fig.3) (Thomson, 2006; Constantinescu et al., 
2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from Lublin and Reingold, Neurology,1996) 
 
a b 
c d 
Figure 3. The patterns and courses of MS. There are four types of MS: Relapsing-Remitting 
MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), and 
Progressive-Relapsing MS (PRMS). a. RRMS is characterized by acute attacks with full 
recovery or with partial recovery. Approximately 80% of patients with MS have RRMS, which is 
characterized by episodes of symptoms (relapse) followed by the absence of symptoms 
(remission). Symptoms may evolve over days and disappear, although this varies between 
patients, and relapse appears approximately every two years. b. SPMS occurs as a result of 
RRMS developing into a progressive state. In this case, the patient previously would have been 
diagnosed with RRMS, but is now presenting with fewer relapses, with continual progression of 
neurologic symptoms. c. PPMS is characterized by progression from onset of disease without 
acute relapses. PPMS occurs when the patient's symptoms steadily increase proportional with 
time, and there are no episodes of relapse or remission. This form of MS has short periods 
where symptoms stabilize or improve slightly. d. PRMS is characterized by progression from 
onset of disease with acute relapses. PRMS is the rarest form of MS, which is expressed as 
gradual worsening with superimposed relapse/remission episodes. 
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2.5 Pathological Features  
The pathology of MS is distinguished from that of other inflammatory 
disease of the nervous system by the presence of large, multifocal, 
demyelinated plaques or lesions (Lassmann, 1998; Prineas, 1985). 
There are four key pathological features of MS: (a) demyelination; (b) 
inflammation; (c) axonal loss or damage; and (d) gliosis 
(Constantinescu et al., 2011).  
(a) Demyelination. The major pathological hallmark of MS is 
demyelination. Demyelination is the pathological process in which 
myelin sheaths are lost from around axons. In the CNS 
demyelination is usually the consequence of a direct insult targeted 
at the oligodendrocyte, the cells that makes and maintains the 
myelin sheath (Franklin and ffrench-Constant, 2008). 
(b) Inflammation. During active disease, demyelination is associated 
with an inflammatory reaction that is orchestrated by activated 
lymphocytes, macrophages, and endogenous glial cells (astrocytes 
and microglia). Inflammation is generally believed to be the main 
trigger of the events leading to CNS tissue damage.  
However, recent evidence suggests that in some cases initial 
damage to neuroglia elements can trigger secondary inflammation 
(Barnett and Prineas, 2004). 
Early MS lesions are characterized by the local accumulation of 
activated CD4+ and CD8+ T-cells around small venules, with CD4+ 
cells predominating (Hauser et al., 1983). Later there is myelin 
degeneration associated with perivascular inflammation consisting 
of T-cells, B-cells, plasma cells and activated macrophages 
(Prineas, 1975). Macrophage/microglia are active participants in 
myelin breakdown; phagocytosis of myelin proteins in the lesions by 
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these cells is a reliable indicator of ongoing demyelinating activity 
(Bauer et al., 1994).  
Based upon pattern and extent of inflammation, white matter 
lesions are usually divided into active, chronic active, or chronic 
inactive (Bo et al., 1994; Trapp et al.,1998; van der Valk and De 
Groot, 2000). 
In active lesions, there is macrophage infiltration throughout the 
lesion; in chronic active lesions, there is macrophage infiltration at 
the lesion border but little infiltration at the lesion center; and in 
chronic inactive lesions, there is little infiltration throughout the 
lesion. In chronic MS, chronic active lesions are the most common 
lesion subtype in the brain, whereas most of the lesions in the 
spinal cord are inactive (Tallantyre et al., 2009).  
The chronic persistence of inflammation in MS lesions may be 
clinically relevant as it may mediate the lesion growth and the 
chronic axonal loss.  
(c) Axonal loss. Although myelin sheaths are the primary target of 
tissue destruction, axons are also affected. Acute axonal injury is 
frequent in actively demyelinating MS lesions. Demyelination can 
be repaired, at least in part, by remyelination, but axonal destruction 
is irreversible (Kornek and Lassmann, 1999). 
Axonal injury in MS plaques occurs in two stages (Kornek et al., 
2000). A high incidence of acute axonal injury is found in lesions 
during the active stage of myelin destruction. The extent of ongoing 
axonal loss correlates with extent of macrophage infiltration (Trapp 
et al., 1998; Ferguson et al., 1997). Thus, even during the earliest 
stages of the disease, every newly formed plaque is associated with 
a significant loss of axons. In addition to axonal degeneration in 
active plaques, there is also a low level of continuous axonal 
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destruction and loss in chronic inactive demyelinating plaques 
(Kornek et al., 2000).  
(d) Gliosis. Gliosis is also a prominent feature of MS, and is 
characterized by astrocyte proliferation, hypertrophy, and increased 
synthesis of glial fibrillary acidic protein, an astrocyte-specific 
protein (Bignami et al.,1972). This reaction is thought to contribute 
to the formation of dense glial scars in the CNS, leading to motor 
and sensory impairment. 
 
2.6 Immunology  
The pathogenesis of MS is determined by the interaction between 
multiple components of the immune system and all elements of the 
CNS (Constantinescu et al., 2001). Following the description of MS by 
Charcot in 1868 (Charcot, 1868), and the observation by Pasteur at the 
turn to the twentieth century (Remlinger, 1905) of acute postvaccinal 
encephalomyelitis in rabies vaccines; Rivers showed in 1933 (Rivers et 
al., 1933) that the injection of spinal cord or brain homogenates into 
healthy primates caused a disease similar to MS, leading to the 
hypothesis that MS is an autoimmune disease. Several decades later, 
investigators began to study systematically the experimental disease in 
rodents and made the seminal observations that still dominate our 
thinking about the pathogenesis of MS (Zamvil et al., 1990). They 
showed that the injection of defined protein components of the myelin 
sheath together with an adjuvant into naive susceptible animals caused 
either an acute, chronic, or relapsing-remitting encephalomyelitis, which 
is now referred to as Experimental Autoimmune Encephalomyelitis 
(EAE). However, current evidence on the induction and perpetuation of 
MS still favors CD4+ autoreactive T cells as a central factor for the 
autoimmune pathogenesis of MS. 
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MS is considered a CD4+ Th1-mediated autoimmune disease (Martin et 
al.,1992; Hafler, 2004). This view is based on the cellular composition of 
brain- and cerebrospinal fluid (CSF)-infiltrating cells. 
The activation of CD4+ autoreactive T cells and their differentiation into 
a Th1 phenotype is a crucial event in the initial steps of MS, and these 
cells are probably also important players in the long-term evolution of 
the disease. Potentially autoreactive CD4+ T cells are activated in the 
periphery by recognizing, for example, a viral peptide in the context of 
costimulatory and other less-defined signals. The initiating antigen 
epitopes show molecular similarity (mimicry) with some CNS antigen or 
a superantigen (Sospedra and Martin, 2005). Following activation, the 
effector CD4+ T cells are capable of producing inflammatory cytokines 
(McFarlard and Martin, 2007).  
Factors that contribute to a proinflammatory environment include a 
number of cytokines from both T cells and antigen-presenting cells 
(APCs) (e.g., IL-12, IFN-γ), the strength of activation, and the infectious 
context. Activated autoreactive T cells adhere to the blood brain barrier 
(BBB) endothelium via adhesion molecules (LFA-1 and VLA-4), 
transmigrate into the brain parenchyma through cerebrovascular unit 
and extravasate into the CNS.  
Once in the CNS, the autoreactive CD4+T cells initiate myelin 
destruction through the activation of resident and infiltrating APCs. The 
activated infiltrating immune cells secrete cytokines and chemokines 
that not only recruit immune cells into the central nervous system, but 
also help to open the BBB. Besides the re-activation of the CD4+ T cells 
that are specific for the initiating antigen, myelin antigens are released, 
phagocytosed, processed, and presented principally within the CNS by 
peripherally derived myeloid dendritic cells (DCs) to naive CD4+ T cells, 
both of which can enter through the compromised BBB (Fig.4). Several 
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mechanisms are still unclear, including what guides autoreactive CD4+ 
T cells to the CNS.  
Subsequently, proinflammatory cytokines (IFN-γ , IL-23, TNF-α, LT) and 
chemokines (RANTES, IP-10, IL-8, and others) (a) activate resident 
cells, such as microglia and astrocytes; (b) recruit other immune cells, 
including monocytes, CD8+ T cells, B cells, and mast cells, from the 
peripheral blood; and (c) orchestrate the formation of the inflammatory 
lesion. 
The formation of the inflammatory lesion is characterized by an open 
BBB with tissue edema after mediator/protease release from mast cells, 
monocytes, and T cells.  
Damage of CNS tissue, i.e., the myelin sheath, oligodendrocytes, and 
axons, occurs already at this early inflammatory stage. During the 
above steps, CD4+ autoreactive T cells are likely driving the process, 
whereas their role in the effector phase is probably secondary. 
Numerous processes may lead to myelin/oligodendrocyte and axonal 
damage, including radicals, TNF-α and direct complement deposition, 
as well as antibody-mediated complement activation and antibody-
dependent cellular cytotoxicity via Fc-receptors, myelin phagocytosis, 
direct lysis of axons by CD8+ cytotoxic T lymphocytes, the secretion of 
proteases, and apoptosis of oligodendrocytes. 
Damage of the target tissue, the central nervous system, is, however, 
most likely mediated by other components of the immune system, such 
as antibodies, complement, CD8+ T cells, and factors produced by 
innate immune cells. Perturbations in immunomodulatory networks that 
include Th2 cells, regulatory CD4+ T cells, NK cells, and others may in 
part be responsible for the relapsing-remitting or chronic progressive 
nature of the disease. However, an important paradigmatic shift in the 
study of MS has occurred in the past decade. It is now clear that MS is 
not just a disease of the immune system, but that factors contributed by 
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the central nervous system are equally important and must be 
considered (Sospedra and Martin, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.7 Glial Cells in Multiple Sclerosis 
Glial cells are fundamental for the control of brain homeostasis, (Fig.5) 
and they represent the intrinsic brain defence system. Neuroglia cells 
are a major component of pathogenesis of neurological disease. 
Neuroglia as a major element of neuropathological processes was 
(Adapted from Miller et al., Nature Reviews Immunology, 2007) 
Figure 4. Epitope spreading cascade during progression of Multiple Sclerosis. The 
activation of the autoreactive CD4
+
 T cells that are specific for the initiating antigen epitope 
(CD4
+
 T cell depicted in green) occurs in the draining lymph node. Following activation, the 
effector CD4
+
 T cells enter the circulation and extravasate into the CNS. Once in the CNS, 
the autoreactive CD4
+
 T cells initiate myelin destruction through the activation of resident and 
infiltrating antigen-presenting cells (APCs). The activated infiltrating immune cells secrete 
cytokines and chemokines that not only recruit immune cells into the central nervous system 
(CNS), but also help to open the blood–brain barrier (BBB). Besides the re-activation of the 
CD4
+ 
T cells that are specific for the initiating antigen, myelin antigens are released, 
phagocytosed, processed, and presented principally within the CNS by peripherally derived 
myeloid dendritic cells (DCs) to naive CD4
+
 T cells, both of which can enter through the 
compromised BBB. TCR, T-cell receptor; MHC (major histocompatibility complex) class II 
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already understood by Rudolf Virchow, who was convinced that 
“Nervenkitt”/Neuroglia is central for neuropathology: “This very 
interstitial tissue of the brain and spinal marrow is one of the most 
frequent seats of mordib change” (Virchow, 1858). All neurological 
diseases, including MS, can be defined as homeostatic failures. Glia 
are the principal homeostatic cells of the nervous system and, 
accordingly, they are integral to homeostatic failures in all neurological 
diseases. For a long time, our perception of brain pathology has 
naturally focused on neurons and on their survival or death. This 
perception is now being challenged, and neuroglia are beginning to be 
recognized as a central element of neurological disease (Giaume et al., 
2007; Verkhatsky et al., 2012). Neurological disorders reflect several 
levels of compromised tissue homeostasis, and the pathological 
response of glia determines the degree of homeostatic loss. Multiple 
Sclerosis can be considered a disease of oligodendrocytes, but all 
neural cell types are involved (Compston and Coles, 2008). The 
pathological response of glia largely determines the outcome and scale 
of neurological disease. The function of neuroglia is neuroprotection in 
MS, glia attempt to maintain tissue and cellular homeostasis. However, 
glia can also be neurodestructive, which serves to clean up the 
compromised tissue and protect the surrounding uncompromised 
cells/tissue (Verkhratsky and Butt, 2013). The precise mechanisms that 
determine the progression of MS, and the role of different glial cellular 
elements in it, remains unresolved.  
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2.7.1 Microglia 
Microglia play the central role in the immune and inflammatory 
response in MS, releasing pro- and anti-inflammatory cytokines and 
chemokines. The accumulation of T and B lymphocytes and the release 
of pro-inflammatory cytokines recruits naïve microglia, which is key step 
in the amplification and local spread of the inflammatory response. 
Activated microglia contribute to inflammation by the release of 
cytokines, with destructive roles (e.g. TNFα and INFγ), and with roles in 
repair and remyelination (e.g. IL-10). Microglia are also important in 
repair by removal of myelin debris, which is inhibitory for remyelinating 
NG2-glia. Chronic activation of microglia leads to neuronal loss in later 
stages of the disease (Verkharatsky and Butt, 2013).  
Figure 5. Glia as homeostatic 
cells of the Nervous System. 
Neuroglia in the CNS is represented 
by highly heterogeneous cellular 
populations of different origin, 
structure and functions: Ependymal 
Cells, Astrocytes, Microglia and 
Oligodendrocytes. One unifying 
fundamental property common for 
all these cell types is their ultimate 
function, the homeostasis of the 
nervous system. This homeostatic 
function of neuroglia is executed at 
many levels, and includes: whole 
body and organ homeostasis, 
cellular, morphological, molecular , 
metabolic, long-range signaling and 
defensive homeostasis. 
 Microglia 
Oligodendrocyte 
Myelinated  
Axon 
Myelin Sheat 
 (cut) 
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2.7.2 Astrocytes 
The reactive astrocytes of MS lesions frequently contain myelin or 
myelin degradation products. In the majority of chronic inactive white 
matter MS lesions, there is prominent astrogliosis, with a dense 
meshwork of glial fibrillary acidic protein (GFAP)-positive processes. In 
active lesions, large hypertrophic astrocytes may be present, which may 
appear to be in close proximity or even contain the cell bodies of one or 
more oligodendrocytes. This process seems to be different from 
phagocytosis. 
Astrogliosis is also detected in diffusely abnormal white matter areas 
with concomitant microglial activation and BBB abnormality. The cause 
of the general astrocyte activation outside of lesions is unclear, possibly 
related to inflammatory mediators, diffusing from lesions, stimulating 
this proliferation. In contrast, in purely cortical lesions, astroglial 
changes are small or absent. 
Astroglial scar has been thought to impair the recruitment of 
Oligodendrocyte Precursor Cells (OPCs) in MS lesions, although direct 
evidence is lacking (Lars Bø et al., 2013). 
 
2.7.3 Oligodendrocytes  
The pathological hallmarks of MS is the white matter lesion, caused by 
loss of myelin and oligodendrocytes. 
Oligodendrocyte loss has been postulated by Barnett (Barnett and 
Prineas, 2004) to be the initial event in MS lesion formation. Certainly in 
the center of chronic inactive lesions, oligodendrocytes are in general 
not detected, but in other lesion types, there is a large degree of 
variability of oligodendrocyte numbers, as high numbers of 
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oligodendrocytes may be present both in active lesions and at the 
inflammatory edge of chronic active lesions. 
A recent study indicates that this variability may be mainly 
interindividual, as in a subgroup of MS patients a high number of 
oligodendrocytes were retained in lesion areas (Patrikios et al., 2006). 
In the chronic MS lesions, oligodendrocyte processes were extended to 
axons but did not seem to be able to initiate the formation of myelin. 
This suggests that there are molecules expressed by demyelinating 
axons in MS lesions that inhibit the initiation of myelination. 
The extent of oligodendrocyte loss in gray matter lesions is similar to 
that in white matter lesions. The mechanisms of oligodendrocyte death 
in MS are not well characterized (Lars Bø et al., 2013).  
 
2.7.4 Oligodendrocyte Precursor Cells (OPCs) 
In MS, oligodendroglial precursor cells (OPCs) are believed to be the 
cells responsible for remyelination. 
“Remyelination” or “myelin repair” is the process in which entire myelin 
sheaths are restored to demyelinated axons, reinstating saltatory 
conduction and resolving functional deficits. 
Following demyelination in the CNS, a demyelinated axon has two 
possible fates (Fig.6). The normal response to demyelination is 
spontaneous remyelination involving the generation of new 
oligodendrocytes. In some circumstances, however, and notably in MS, 
remyelination fails, leaving the axons and even the entire neuron 
vulnerable to degeneration that largely accounts for the progressive 
clinical decline (Franklin and ffrench-Constant, 2008). 
In demyelinated lesions depleted of oligodendroglial lineage cells, 
OPCs occur with onset of remyelination suggesting that OPCs and not 
mature oligodendrocytes are responsible for remyelination (Fancy et al., 
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2004; Levine and Reynolds, 1999; Watanabe et al., 2002). In the adult 
brain and spinal cord, OPCs, also known as NG2 cells, are ubiquitous 
and represent a large percentage of the total cell population, as much 
as 9% of cells in white matter and 3% in gray matter (Nishiyama, 2001). 
In response to a demyelinating lesion, NG2 cells start proliferating and 
are recruited to the demyelinated axons, where they differentiate into 
mature, myelin-forming oligodendrocytes. In response to injury, local 
OPCs undergo a switch from an essentially quiescent state to a 
regenerative phenotype. This activation is the first step in the 
remyelination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Following recruitment, the OPCs must differentiate into remyelinating 
oligodendrocytes. This differentiation phase encompasses three distinct 
steps: establishing contact with the axon that is to be remyelinated, 
expressing myelin genes and generating a myelin membrane, and 
finally wrapping and compacting the membrane to form the sheath. 
OPCs proliferate and migrate before differentiating into late 
oligodendrocyte progenitors [premyelinating oligodendrocytes (preOLs)] 
Adapted  from Franklin and ffrench-Constant., Nature Neuroscience, 2008  
Figure 6. The fate of demyelinated axons. a. Following demyelination in the CNS, a 
demyelinated axon has two possible fates. The normal response to demyelination, at least in 
most experimental models, is spontaneous remyelination involving the generation of new 
oligodendrocytes. In some circumstances, however, and notably in Multiple Sclerosis, 
remyelination fails, leaving the axons and even the entire neuron vulnerable to degeneration 
that largely accounts for the progressive clinical decline that is associated with demyelinating 
diseases.  
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which undergo extensive cellular growth and process elaboration and 
mature into myelinating oligodendrocytes (OLs) (Jakovcevski and 
Zecevic, 2005; Kessaris et al., 2006; Jakovcevski et al., 2009; Rowitch, 
2004). The different stages of maturation toward myelinating 
oligodendrocytes can be identified by cell type-specific markers. In the 
past decade, various markers have been identified that show lineage- 
and stage-specific expression. The markers platelet-derived growth 
factor receptor-alpha (PDGFRα), NG2, a membrane chondroitin sulfate 
proteoglycan, Olig2, Nkx2.2, Sox10, and Olig1 (nuclear) are 
characteristic of OPCs. O1 [also known as galactocebroside (GalC)], 
O4 antigen and 2‟-3‟-cyclic nucleotide-3‟-phosphodiesterase (CNPase) 
mark intermediate preOLs, whereas myelin basic protein (MBP), myelin 
proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG) 
and Olig1 (cytoplasmic) are typical of mature myelinating 
oligodendrocytes. (Fig.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted by Zhang, Nature Neuroscience, 2001  
Figure 7. Morphological and antigenic markers for oligodendroglia during development. 
The differentiation of oligodendrocytes from their progenitors follows a stepwise morphological 
transformation from bipolar progenitors to pro-oligodendrocytes bearing multiple processes 
(immature), membrane-sheath-bearing mature oligodendrocytes, and, finally, myelinating 
oligodendrocytes. Accompanying this morphological change is the sequential expression of 
molecular markers: A2B5 antigen, platelet-derived growth factor receptor-(PDGFR) and 
chondroitin sulphate proteoglycan NG2 in progenitors, O4 antigen in pro-oligodendrocytes, 
galactocerebroside (GC or GalC or O1 antigen) and 2',3'-cyclic nucleotide 3'-
phosphodiesterase (CNPase) in mature oligodendrocytes, and most myelin proteins - myelin-
associated glycoprotein (MAG), myelin basic protein (MBP) and proteolipid protein (PLP) - in 
myelinating oligodendrocytes.  
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2.8 Current treatments and future perspectives in therapeutic 
strategies for Multiple Sclerosis 
Currently, the drugs for MS are exclusively immunomodulatory 
therapies. These drugs are relatively effective at preventing new 
demyelinated lesions from forming and significantly impeding relapsing-
remitting disease progression, but are ineffective at preventing the 
transition to or advancement of progressive MS. At this chronic stage 
neurodegeneration becomes increasingly evident leading to the 
accumulation of irreversible clinical disability (Compston and Coles, 
2008). At present, approximately 50% of people affected by MS are at 
the progressive stage of the disease illustrating the critical need for 
developing additional therapeutic strategies to protect oligodendrocytes 
and bolster regeneration in combination with current immunotherapies. 
There are three principal approaches to treating MS: 1) halting the 
pathologic immune response, 2) protecting the CNS from further 
damage, and 3) repairing the damage through the regeneration of new 
myelin sheaths, with the overarching goals being to restore conduction 
and prevent further axonal loss (Rodgers et al., 2013).  
The landscape for MS therapies is undergoing a rapid expansion as 
knowledge accumulates on how aberrant immune responses produce 
demyelinating injury and how the CNS is able to regenerate myelin. The 
early broad-based immunosuppressive drugs are giving way to 
targeted, antigen-specific approaches minimizing side effects and 
maximizing clinical benefit. At the same time decades of work suggest 
that immunomodulation alone will only go so far and that strategies to 
protect oligodendrocytes and promote remyelination should be 
considered in parallel, combinatorial therapeutic approaches. Many 
repurposed drugs are showing promise for protecting oligodendrocytes, 
and remyelination strategies focusing on antibodies and 
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pharmacological targets have shifted the focus from cellular 
replacement to enhancing endogenous repair (Rodgers et al., 2013). 
 
2.8.1 Immune-modulating Therapies 
The ten existing disease-modifying treatments for MS target the 
immune compartment (Derwenskus, 2011). Early approaches aimed to 
limit activation of pathologic immune cells were relatively non specific in 
their scope. Early drugs interferon-beta (Avonex, Rebif, Betaseron 
Extavia) and glatiramer acetate (Copaxone), a synthetic copolymer, are 
both administered subcutaneously to suppress multiple cell types 
including antigen presenting cells and TH1 and TH17 helper subsets 
cells and shift the immune system towards a regulatory phenotype 
(Lalive et al., 2011). Mitoxantrone (Novatrone), a synthetic 
antineoplastic drug, induces apoptosis in highly proliferative cells and 
suppresses macrophages, B cells, and TH cells (Derwenskus, 2011). 
Recent work in autoimmunity has sought to refine the therapeutic 
approach in new ways, more specifically targeting the pathologic 
immune compartment without compromising the entire arm of the 
adaptive immune response thus minimizing side effects and any risks of 
opportunistic infection. Two current therapies limit T cell migration: 
fingolimod (Gilenva) constrains T cell migration from lymph nodes, 
whereas natalizumab (Tysabri) blocks T cell infiltration across the 
blood-brain barrier into the CNS. 
 
2.8.2 Oligodendrocyte Protective Therapies 
The majority of drugs under investigation to protect oligodendrocytes 
from apoptosis were first discovered for their immunomodulatory or 
neuroprotective capabilities in other capacities. In the context of MS, it 
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is often poorly understood whether the beneficial effects are due to 
immune modulation, neuroprotection, or both. Indeed uncoupling these 
effects is particularly difficult as CNS degeneration is so intimately 
associated with inflammation. In light of a combination therapeutic 
approach, drugs that protect oligodendrocytes from apoptosis are likely 
to be most effective when used in combination with systemic immune 
modulation whether in cases of acute or chronic inflammation. Current 
data highlight the importance of proper timing in CNS-protective drug 
treatments as some prove to be most efficacious in early relapsing-
remitting disease associated with deleterious inflammation. In this vein 
neuroprotective drugs may be unnecessary once immune tolerance has 
been established, particularly if tolerance can be induced early in 
disease and proves to have long-lasting effects (Rodgers et al., 2013). 
 
2.8.3 Remyelination Enhancing Therapies 
The third component to a combinatorial therapeutic approach for MS is 
to enhance regeneration in the absence of the pathologic immune 
response and primary CNS damage. Whilst there are no remyelination-
enhancing therapies clinically available at present, research in this area 
is developing, with the focus on two major approaches: transplantation 
of exogenous cells and stimulation of the endogenous repair process. 
Both approaches have their advantages and disadvantages, and it has 
become clear, particularly in recent studies, that is not possible to draw 
a complete distinction between these two approaches (Crawford et al., 
2013).  
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2.9 Animal Models in Multiple Sclerosis Research 
A number of animal models have been developed in order to 
understand a variety of aspects of human MS. The main driving force 
for animal studies stems from the following limitations of human studies: 
overall limited access to human MS tissue, biopsies are rarely 
performed and autopsy samples are usually biased towards a chronic, 
burnt-out stage; experimental circumstances can‟t easily be modified in 
clinical trials and mechanistic studies addressing disease 
pathomechanisms can‟t readily be performed in patients.  
There is no single animal model that can capture the entire spectrum of 
heterogeneity of human MS and its variety in clinical and radiological 
presentation. However, over the last several decades, useful and 
relevant animal models have been developed that represent selected 
aspects of the human disease. Depending on the specific research 
question, the rational selection of appropriate animal models is likely to 
yield outcomes that will result in translatable findings applicable to MS. 
Despite the clearly existing limitations, basic science MS research will 
continue to rely on these models for new drug development and for 
understanding the ramifications and diversity of pathomechanism in MS 
(Denic A. et al., 2011). 
The most commonly studied animal models of MS are (1) the purely 
autoimmune experimental autoimmune/allergic encephalomyelitis 
(EAE), (2) viral induced models, mainly Theiler‟s murine 
encephalomyelitis virus (TMEV) infection and consequential chronic 
demyelination and (3) toxin-induced models of demyelination, including 
the cuprizone model and focal demyelination induced by lyso-
phosphatidylcholine (lysolecithin). 
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2.9.1 Experimental Autoimmune Encephalomyelitis (EAE) 
Experimental Autoimmune Encephalomyelitis (EAE) is the most 
commonly used experimental model for the human disease MS. EAE is 
a complex condition in which the interaction between a variety of 
immunopathological and neuropathological mechanisms leads to an 
approximation of the key pathological features of MS: inflammation, 
demyelination, axonal loss and gliosis. The counter-regulatory 
mechanisms of resolution of inflammation and remyelination also occur 
in EAE, which, therefore can also serve as a model for these 
processes. EAE is a good model for studying MS mechanisms, even 
more so than for testing or developing drugs (Farooqi et al., 2010).  
A major difference between MS and EAE is that the latter requires an 
external immunization step to develop, whereas in humans, the 
sensitization to autoantigens is obviously not artificially induced (Gran et 
al., 2007). Sensitization to myelin antigens in EAE typically occurs 
through the use of adjuvant, usually containing bacterial components 
highly capable of activating the innate immune system via pattern 
recognition receptors (Libbey and Fujinami, 2010).  
EAE can be induced in a multitude of species and strains. Interestingly, 
humans were the first species where sensitization with nervous tissue 
led to an inflammatory demyelinating CNS disease. This occurred as a 
rare complication of rabies vaccination with virus grown on rabbit spinal 
cord (Sabin and Wright, 1934). It was subsequently shown that the 
resultant encephalomyelitis was not due to rabies, but to an 
autoimmune response triggered by the spinal cord contaminant of the 
vaccine. Rivers in 1933 developed EAE in an attempt to understand 
better the pathogenesis of this post-vaccinal encephalomyelitis (Zinsser 
and Tang, 1926; Rivers and Stewart, 1928; Rivers et al., 1933; Rivers 
and Schwentker, 1935). Since then, EAE has been induced in a variety 
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of rodents and monkeys, providing models of acute monophasic, 
relapsing–remitting and chronic progressive CNS inflammation.  
„Active‟ EAE is induced by immunization with CNS tissue or myelin 
peptides, such as MBP, MOG and PLP in Complete Freund‟s Adjuvant 
(CFA), with high incidence of disease induced in susceptible animal 
strains (Stromnes and Goverman, 2006). 
By contrast, „passive‟ or adoptive-transfer EAE (AT-EAE) can be 
induced in recipient animals by transferring pathogenic, myelin-specific 
CD4+ T cells generated in donor animals by active immunization 
(Stromnes and Goverman, 2006). The latter type of EAE was 
instrumental in establishing the key role of myelin-reactive T cells in 
disease pathogenesis (Pettinelli and McFarlin, 1981). 
A frequently used EAE model is induced in the C57BL/6 mouse by 
immunization with MOG35–55 in CFA. The immunization can induce 
monophasic or a chronic, sustained form of EAE. The former is 
characterized by multifocal, confluent areas of mononuclear 
inflammatory infiltration and demyelination in the peripheral white matter 
of the spinal cord (Day, 2005). Macrophages and CD4+ T cells are the 
main cell types in the inflammatory infiltrate. In the brain, there is 
meningitis and perivascular inflammatory cuffing in the cerebellum and 
hindbrain white matter.  
In conclusion, EAE has contributed to the development, validation, and 
testing of MS drugs and even more remarkably, to the understanding of 
the pathogenesis of MS.  
 
2.9.2 Virus Induced Demyelination 
Epidemiological studies have put forward a hypothesis that a viral 
infection early in life, in the presence of a specific genetic background, 
may result in immune mediated attack against CNS tissue (Poser, 
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1986). However, to date there is no specific virus that has been 
identified as a potential cause or contributor to MS (McFarlin and Mc 
Farland, 1982). To model the contribution of viruses in human MS, 
some investigators utilize virus induced demyelination models. 
Experimentally, demyelinating disease in susceptible mouse strains is 
induced by intracerebral infection with TMEV. TMEV (Theiler‟s murine 
encephalomyelitis virus) is a mouse enteric pathogen that belongs to 
the single-stranded RNA picornaviruses. Unlike EAE, the disease is 
always chronic-progressive in susceptible mice and there is no 
consensus about the exact mechanism of demyelination in the TMEV 
model (Denic A. et al., 2011). 
 
2.9.3 Toxin Induced Demyelination 
The two most widely used toxins to induce demyelination in animal 
models of MS are lysolecithin and cuprizone. Lysolecithin is an activator 
of phospholipase A2 and cuprizone is a copper chelator. Compared to 
EAE and virus induced demyelinating syndrome, toxin induced 
demyelination models do not attempt to mimic MS as a disease, but are 
mainly established as systems to study the process of focal 
demyelination and remyelination (Blakemore and Franklin, 2008). 
 
. 
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II. AIM OF THE STUDY 
MS is an inflammatory demyelinating autoimmune disorder of the CNS. 
Current medical treatment mainly influences disease progression via 
immunomodulatory or immunosuppressive actions. Indeed, MS 
research has been foremost focused on inflammation in the CNS, but 
more recent evidence suggests that chronic disability in MS is caused 
by neurodegeneration (Ellwardt and Zipp, 2014). Basic research on the 
MS has been performed mainly on its animal model namely 
Experimental Autoimmune Encephalomyelitis (Trafreshi et al., 2005). 
EAE is a complex condition in which the interaction between a variety of 
immunopathological and neuropathological mechanisms leads to an 
approximation of the key pathological features of MS: inflammation, 
demyelination, axonal loss and gliosis. The counter-regulatory 
mechanisms of resolution of inflammation and remyelination also occur 
in EAE, which, therefore can also serve as a model for these processes 
(Constantinescu et al., 2011). 
The dysregulation of [Ca2+]i and [Na
+]i homeostasis is involved in 
neuronal and glial injury occurring in several neurodegenerative 
diseases, including MS. The Na+/Ca2+ exchanger (NCX), a 
transmembrane domain protein, which, by operating in a bidirectional 
way, couples the efflux of Ca2+ to the influx of Na+ into the cells or, 
viceversa, the influx of Ca2+ to the efflux of Na+, is involved in the 
regulation of diverse neuronal and glial cell functions (Annunziato et al., 
2004). Recent evidence point out that the isoform-3 of the Na+/Ca2+ 
exchanger is a new potential therapeutic target for neuroprotection 
(Pignataro et al., 2004; Molinaro et al., 2008; Pignataro et al., 2011). In 
agreement with the beneficial role of this exchanger, it has been 
demonstrated that NCX3-deficient mice showed skeletal muscle fiber 
necrosis and impaired neuromuscular transmission, which is clinically 
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associated with reduced motor activity, weakness of forelimb muscles, 
and fatigability (Sokolow et al., 2004). 
In a paper recently published by our research group it has been 
demonstrated that calcium signaling mediated by NCX3 isoform has a 
crucial role in the progression of OPCs into mature oligodendrocytes. 
Interestingly, spinal cords isolated from ncx3-/- mice were smaller than 
those isolated from wild-type, congenic, ncx3+/+ mice. Furthermore, 
NCX3-deficient mice showed hypomyelination that is accompanied by 
an augmented expression of the OPC marker NG2 and a reduction of 
spinal cord size (Boscia et al., 2012). More recently, in an attempt to 
understand the molecular composition of myelin membranes, 
Gopalakrishnan et al., (2012) identified the isoform-3 of Na+/Ca2+ as a 
common protein to human and murine myelin proteome. Therefore, the 
decreased myelination observed in the ncx3-/- mice (Boscia et al., 
2012) might be caused by a decrease in the number of differentiated 
oligodendrocyte and/or by a decreased ability of oligodendrocytes to 
produce myelin.  
In light of this, in the present study we asked whether the NCX3 
exchanger might have a role in the susceptibility of the disease and 
during the pathophysiological responses in a mouse model of Multiple 
Sclerosis. To address these questions we used the EAE as a murine 
model for MS. 
The study objectives included: 
1) To assess all inflammatory, neuronal and glial responses after 
EAE immunization. Morphological analyses were performed at 
different time points during disease progression in order to 
characterize the patterns of demyelination, axonal loss and glial 
activation. 
 
47 
 
2) To provide a clear picture of NCX3 expression and distribution in 
the white matter spinal cord during EAE course. Biochemical and 
immunohystochemical analyses were performed with the aim to 
analyze the expression profile of NCX3 protein in the spinal 
cords of control and EAE mice. Co-expression analyses of NCX3 
with both neuronal and oligodendrocyte lineage markers were 
performed in order to evaluate the involvement of this isoform 
during EAE responses. 
 
3) To establish the role played by NCX3 in EAE severity and 
progression. Behavioural and morphological analyses were 
performed in NCX3 congenic wild type and in NCX3 knockout 
mice exposed to EAE with the aim to study the neurological 
deficits, the demyelination, the axonal loss and the 
oligodendroglial responses during the pathology. 
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III. MATERIALS AND METHODS 
1. Animals 
Experiments were performed on C57BL/6, ncx3 congenic wild-type 
(ncx3+/+), ncx3 heterozygous (ncx3+/-) and knockout (ncx3-/-) mice 
(Sokolow et al., 2004). C57BL/6 mice were purchased by Charles River. 
The generation of NCX3 knockout mouse has been described by 
Sokolow et al. (2004). In particular, the ncx3 gene includes nine exons 
spanning a region of about 150 kb. To constructed a mutant allele, the 
exon 2 of the murine ncx3 gene (GeneBank, accession number 
AF321404), which encodes for the first two-thirds of the protein, was 
cloned from a 129/Sv genomic phage library. A targeting vector was 
constructed by inserting the neomycin resistance cassette (neo) into the 
unique EcoRI restriction site of that exon. The insertion of the neomycin 
resistance cassette in the second exon of the ncx3 gene created a null 
mutation. After electroporation with the targeting vector, the 
recombinant embryonic stem (ES) clones were identified by DNA 
hybridization and used to produce chimeric mice. Transmission of the 
mutant allele produced NCX3 heterozygous mice (ncx3+/-) that were 
mated to generate NCX3 null mutants (ncx3-/-) (Sokolow et al., 2004). 
Female mice, aged between 6-8 weeks and weighing 19-20 g were 
housed under diurnal lighting conditions (12 hr darkness and 12 hr light) 
and had free access to food and water. All of the mouse models were 
bred in ventilated rooms, in a germ-free facility, under controlled 
conditions of light, temperature and humidity. Experiments were 
performed on mice according to the international guidelines for animal 
research and approved by the Animal Care Committee of “Federico II” 
University of Naples, Italy. 
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2. Genotyping of Mice 
DNA extraction from mouse tail. To genotype the mice, DNA was 
extracted from mouse tail. From 0.7 to 1 cm of the mouse tail was 
incubated in 600 µl digestion buffer containing proteinase K (1 mg/ml) at 
55°C over night. At the digestion mixture were added 500μl of 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and it was centrifuged at 
13.000 rpm for 10 minutes at room temperature to collect undigested 
tail debris. Finally, the DNA containing supernatant was removed and 
was added 1 ml of cold 95% Ethanol and inverted to mix. The DNA was 
isolated and resunspended in 50 µl of steril water and was allowed to 
dissolve. 
Standard Polymerase Chain Reaction (PCR) Amplification. Genotyping 
was performed using PCR amplification. PCR was carried out in 200μl 
thin walled PCR tubes using 1 μl of DNA, 2 µl of 2.5 mM of dNTPs 
consisting of dATP, dTTP, dGTP and dCTP (Lucigen), 0.125 μl of Taq 
polymerase (EconoTaq DNA Polymerase 1000 U at 5U/µl, Lucigen), 2.5 
μl of 10x Buffer (EconoTaq Buffer with Mg, Lucigen),1 μl of 0.2 µg/µl 
forward primer, 1 μl of 0.2 µg/µl reverse primer and 17.37 μl of sterile 
filtered distilled water. In one reaction, two primer pairs were used to 
amplify regions of the target genes. Positive and negative control 
samples were also used. A positive control (DNA of known genotype) 
was used to make sure all the reagents were still working appropriately. 
In addition to this, a negative control containing sterile filtered water was 
included to make sure the reaction mixture was not contaminated with 
another source of DNA. 
Agarose Gel Electrophoresis. PCR products were separated by 
electrophoresis on a 1.5 % agarose gel, and visualised under UV light 
followed ethidium bromide staining. A 100 kb DNA ladder was also 
loaded onto the gel to permit size analysis of PCR products. 
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Electrophoresis was performed at 100 v for approximately 45 minutes 
allowing the fragments to completely separate. The DNA bands were 
visualised by placing the gel into a UV transluminator. 
 
3. Active Induction of EAE in Mice 
EAE was induced by active immunization with the peptide 
corresponding to the immunodominant epitope of Myelin 
Oligodendrocyte Glicoprotein  (MOG), the peptide 35-55 (p35-55). A 
p35-55 sequence of MOG (MOG35-55): M-E-V-G-W-Y-R-S-P-F-S-R-V-V-
H-L-Y-R-N-G-K was synthesized by INBIOS srl, Naples, Italy. Mice 
were immunized with 200µg of MOG35-55 emulsified in Complete 
Freund‟s Adjuvant (CFA) (DIFCO) supplemented with 4 mg/ml killed 
mycobacterium tuberculosis. A volume of 0.1 ml of the emulsion was 
injected subcutaneously (s.c.) for each mouse. Mice also were 
administered intraperitoneal (i.p.) pertussis toxin (PT) (Sigma). PT was 
injected immediately and 48 hours later. Pertussis toxin can promote 
the activation of T cells and contribute to the destruction of blood-brain 
barrier (Hofstetter et al., 2002). PT enhances EAE development by 
providing additional adjuvant and facilitating entrance of autoimmune T 
cells into the CNS. Control mice were injected with equivalent amounts 
of CFA alone. 
 
4. Clinical Scoring of EAE 
Mice were monitored daily, starting on the day of the immunization (day 
0) and continuing until day 50. MOG-immunized mice were checked for 
clinical signs of EAE and graded on a scale of increasing severity. 
Clinical signs and ascending paralysis were assessed on a six-stage 
scale of 0-5. Disease scores were assigned as shown in Table 1. 
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Fractional scores result either from calculating the mean of scores from 
a group of animals or from assigning fractional scores for partial but 
distinct phenotypes; for example, when the distal tail droops while the 
tail can be raised overall, a score of 0.5 was assigned and when one 
leg is dragging but the other bears a large fraction of the body‟s weight, 
a score of 2.5 or 2.75 was assigned. 
 
Table 1.  Clinical Scoring of EAE 
Score Clinical Observations 
 
0.0  
  
 
No obvious changes in motor function compared to non-
immunized mice. 
When picked up by base of tail, the tail has tension and is 
erect. Hind legs are usually spread apart. When the 
mouse is walking, there is no gait or head tilting. 
 
0.5 
 
Tip of tail is limp. 
When picked up by base of tail, the tail has tension except 
for the tip. Muscle straining is felt in the tail, while the tail 
continues to move. 
 
1.0  
 
 
Limp tail. 
When picked up by base of tail, instead of being erect, the 
whole tail drapes over finger. Hind legs are usually spread 
apart. No signs of tail movement are observed. 
 
1.5 
 
Limp tail and hind leg inhibition. 
When picked up by base of tail, the whole tail drapes over 
finger. When the mouse is dropped on a wire rack, at least 
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one hind leg falls through consistently. Walking is very 
slightly wobbly. 
 
2.0  
 
 
Limp tail and weakness of hind legs. 
When picked up by base of tail, the legs are not spread 
apart, but held closer together. When the mouse is 
observed walking, it has a clearly apparent wobbly walk. 
One foot may have toes dragging, but the other leg has no 
apparent inhibitions of movement. 
 
2.5 
 
Limp tail and dragging of hind legs. 
Both hind legs have some movement, but both are 
dragging at the feet (mouse trips on hind feet). 
 
  - OR - 
 
No movement in one leg/completely dragging one leg, but 
movement in the other leg. 
 
 
3.0  
 
 
Limp tail and almost complete paralysis of hind legs. One 
or both hind legs are able to paddle, but neither hind leg is 
able to move forward of the hind hip. 
 
  - OR - 
 
Limp tail with paralysis of one front and one hind leg. 
 
3.5 
 
Mouse is moving around the cage, but the hind quarters 
are flat. 
 
4.0  
 
 
Limp tail, complete hind leg and partial front leg paralysis. 
Mouse is minimally moving around the cage but appears 
alert and feeding. 
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4.5 
 
Complete hind and partial front leg paralysis, no 
movement around the cage. Mouse is not alert. 
Mouse has minimal movement in the front legs. The 
mouse barely responds to contact. 
Euthanasia is recommended. When the mouse is 
euthanized because of severe paralysis, a score of 5.0 is 
entered for that mouse for the rest of the experiment. 
 
5.0 
 
 
Mouse is spontaneously rolling in the cage (euthanasia is 
recommended). 
  - OR - 
Mouse is found dead due to paralysis. 
  - OR - 
Mouse is euthanized due to severe paralysis. 
 
 
 
 
5. Western Blotting 
Spinal cord tissues were collected for biochemical studies at different 
time points after immunization. Protein samples, isolated using tissue 
lysis buffer, were separated on 14% polyacrylamide gel and 
electrophoretically transferred onto nitrocellulose membranes. The 
membranes were blocked with 5% non fat dry milk. Filters were probed 
using the primary monoclonal antibody anti-NCX3 (1:1000, Trans Genic 
Inc.) for over night incubation at 4°C. The membranes were incubates 
with peroxidase-conjuigated secondary antibody for 1 hour at room 
temperature and proteins were visualized using the enhanced 
chemiluminescence system (Amersham-Pharmacia Biosciences LTD, 
Uppsala, Sweden). 
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6. Immunohistochemistry (IHC) 
Mice were anesthetized with gas anesthesia (SevoFlo, Abbott) and 
perfused transcardially with 4% wt/vol. paraformaldehyde and 
15% wt/vol. picric acid in phosphate buffer. Using a fine forceps, 
vertebra were removed and spinal cords were isolated. Spinal cords 
were cryoprotected in sucrose, frozen in OCT, and sectioned coronally 
at 40 μm on a cryostate. The sections were blocked with 3% Bovine 
Serum Albumin (BSA). After blocking, sections were incubated with 
primary antibodies for 48 hr. The primary antibodies used in these 
experiments were the following: polyclonal anti-NF200 (1:1000, Sigma); 
monoclonal anti-MBP (1:400, Covance); monoclonal anti-Iba1(1:2000, 
WAKO); polyclonal anti-GFAP (1:1000, Sigma); monoclonal anti-NCX3 
(1:300, Trans Genic Inc.); polyclonal anti-MBP (1:2000, Millipore); 
polyclonal anti-NG2 (1:1000, Millipore); polyclonal anti-GalC (1:500, 
ProteinTech); polyclonal anti-CNPase (1:200, santa Cruz Biotechnology 
Inc.). For double immunofluorescence sections were incubated with 
corresponding fluorescence labeled secondary antibodies (Alexa-488- 
or Alexa-594- conjugated anti-mouse or anti-rabbit IgGs). Hoechst 
33258 was used as nuclear stain. For immunoenzymatic staining, 
sections were instead incubated with biotinilated secondary antibodies 
(anti-mouse or anti-rabbit, Vector), the peroxidase reaction was 
developed using 3-3‟-diaminobenzidine/4HCl as a chromogen. Because 
no immunoreactivity differences were found between control and CFA-
injected animals, the data are presented as a comparison of MOG35-55-
immunized and CFA-injected mice. 
 
7. Confocal Microscopy and Image Analysis 
Images were observed using a Zeiss LSM 710 laser scanning confocal 
microscope. Single images were taken with an optical thickness of 0.7 
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mm and a resolution of 1024x1024. All images were obtained with a 
20x, 40x, 60x or 100x objectives with identical laser power setting. The 
fluorescence intensity and the % of colocalized points on coronal tissue 
sections from spinal cord were quantified in terms of pixel intensity 
value by using the NIH image software.  
The number of cells was determined in the white matter of the spinal 
cord by manual counting at 40x or 60x magnification only cells with 
clearly a visible cell body and profiles were counted. 
 
8. Statistical Analysis 
The data are expressed as the mean±S.E.M. of the values obtained in 
three separate experiments. Statistical comparisons between controls 
and treated groups were performed by one-way analysis of variance 
followed by Newman–Keuls‟ test. P*<0.05 was considered significant. 
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IV. RESULTS 
1. MOG35-55-induced EAE in C57BL/6 mice reproduced the key 
pathological features of MS 
The EAE clinical course was first characterized by a pre-onset stage (0-
10 days post immunization, dpi) then, by an acute disease onset (10-15 
dpi) characterized by a peak disease stage (15-25 dpi) followed by a 
consecutive chronic phase lasting up to 50 days, the latter time point at 
which the animals were analyzed (Fig.8A). During the pre-onset phase, 
mice did not show any visible motor defects. The first clinical sign of 
EAE, indicated by a loss of tail tonicity, was observed around 10 days 
after the immunization. The increase in clinical score corresponded to 
the decline in body weight (Fig. 8B). At this time point mice developed a 
weak or flaccid tail and started to show signs of motor dysfunction. 
During the peak stage mice progressively lost the ability to move the 
hind legs and a significant weight loss occurred. At this stage the 
animals reached the highest clinical EAE score including loss of tail 
tonicity and paralysis of hindlimbs. The chronic phase was the recovery 
stage of EAE; most of the mice had a tail that was no longer limp but 
was not normal either; it felt rigid and was "hooked". The hind legs 
started moving. During the chronic phase the EAE clinical scores 
improved. Control mice did not show weight loss or neurological deficits 
at any time point following CFA injection (Fig. 8A). In order to correlate 
the clinical motor deficits observed in MOG-immunized mice to the 
cellular and molecular events occurring during the EAE disease course, 
we analyzed by means of confocal double immunofluorescence 
experiments, inflammation, demyelination and axonal loss occurring in 
the brain and spinal cord of EAE mice. The experiments performed in 
the cerebellum and in the other brain regions revealed that the lumbo-
thoracic spinal cord was much more affected by the EAE model (data 
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not shown). Thus, we focused our subsequent studies only within this 
CNS area.  
Confocal double immunofluorescence experiments performed with the 
axonal marker NF200 and the myelin marker MBP in the presence of 
the nuclear marker Hoechst revealed that a significant reduction in both 
MBP and NF200 immunoreactivity was detected in several plaques 
troughout the white matter tracts at peak stage. At this stage, the 
plaques were easily identified by the intense labelling of cellular 
infiltrates with the nuclear marker Hoechst (Fig. 8C, c-d). During the 
chronic stage, the number of infiltrates, detected by Hoechst staining, 
appeared strongly reduced, and several larger regions of reduced MBP 
and NF200 fluorescence staining were observed (Fig. 8C, e-f). In order 
to characterize the pattern of microglial and astocytic activation in EAE 
spinal cord we performed colocalization experiments with the microglial 
anti-Iba1 marker and the astrocytic marker anti-GFAP in the presence 
of the nuclear marker Hoechst. Immunofluorescence experiments 
revealed that the activation of both microglia and astrocytes was higher 
21 dpi both in the white and grey matter of spinal cord (Fig. 8C, i-j). By 
contrast, their labelling appeared strongly reduced in the grey matter at 
chronic stage, but it remained still elevated within demyelinated regions 
at chronic stage (Fig. 8D, k-l).  
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A B 
C 
Figure 8. Pathological features of MOG35-55-induced EAE in C57BL/6 mice. Assessment of EAE 
clinical symptoms (A) and body weight progression (B) in MOG35-55-immunized mice compared with 
vehicle-treated mice during pre-onset, onset, peak and chronic stages. Results represent average 
(mean±S.E.M.) of the data obtained from 6 animals per group in three independent experimental 
sessions. (C) Confocal double-labelling experiments showing MBP (red) - NF200 (green) (a-f)  and GFAP 
(red) - Iba1 (green) (g-l) immunoreactivities in the spinal cord of control (a,b,g,h) and EAE-affected mice 
during the Peak (c,d,i,j) and Chronic (e,f,k,l) stages. Scale bars: 200µm (a, c, e, g, i, k); 20µm (b,h); 50µm 
(d,f,j,l). 
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2. Up-regulation of NCX3 protein levels in the spinal cord 
during EAE progression 
 
In order to investigate NCX3 protein expression and distribution in 
spinal cord tissue of healthy and EAE mice, biochemical and 
immunohistochemical analyses were performed at different time points 
during EAE disease course. 
Western Blotting analysis performed on spinal cord tissue homogenates 
revealed that NCX3 protein levels were progressively up-regulated 
during EAE progression. This effect was more significant at chronic 
stage (Fig. 9A).  
Single immunohistochemical experiments performed with anti-NCX3 
antibody in the white matter spinal cord of control and EAE mice 
revealed a very distinctive expression pattern of NCX3 exchanger being 
localized not only to selective white matter axonal tracts, but also to 
intensely stained cells which resembled oligodendroglial lineage 
morphology (Fig. 9B). Among the different axonal tracts, NCX3 
exchanger was intensely detected in the lateral tracts (Fig. 9B, a,b,e), 
moderately detected in the anterior tracts (Fig. 9B, h,i), but barely 
detected in the posterior tracts (Fig. 9B, l,m). Along the lateral and 
anterior tracts, the ascendent spinocerebellar tract and the descendent 
anterocorticospinal tract, appeared the most intensely immunostained. 
During the peak and chronic stages NCX3 axonal immunoreactivity 
appeared reduced. At these stages NCX3 staining was detected in a 
large number of cells with oligodendroglia-like morphology. This effect 
was particularly evident at chronic stage in the white matter lateral 
tracts (Fig. 9C, c,d,f,g,j,k,n,o). 
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A 
B 
Figure 9. Expression profile of NCX3 protein in the spinal cord of control and EAE mice. (A) 
Western blot and densitometric analysis of NCX3 protein levels in spinal cord tissue homogenates during 
EAE progression. The data were normalized on the basis of α-tubulin levels and expressed as 
percentage of control. The values represent the means±S.E.M. (n=3-4). *P<0.05 versus control. (B) 
Single immunohistochemical experiments with anti-NCX3 antibody (a-o) in control (a,b,e,h,i,l,m) and in 
EAE affected-spinal cord during the Peak (c,f,j,n) and Chronic (d,g,k,o) stages. Analysis were performed 
in the lateral (a-g), anterior (h-k) and posterior (l-o) white matter axonal tracts. Panels e-g show higher 
magnification images of the distinctive expression pattern of NCX3 in the lateral tracts. Scale bars: 
200µm (a); 50µm (h); 100µm (l); 20µm (b,c,d,i,j,k,m,n,o); 10µm (e,f); 5µm (g). 
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3. NCX3 co-expression with the myelin marker MBP and the 
axonal marker NF200 was reduced during EAE progression 
 
To investigate the distribution of NCX3 within myelinated or 
demyelinated axons during EAE progression we performed confocal 
double immunofluorescence experiments of NCX3 antibody with the 
myelin marker MBP or the axonal marker NF200. Confocal double 
immunofluorescence experiments of NCX3 with the myelin marker MBP 
revealed a discrete overlapping of these two proteins in the white matter 
spinal cord of control animals (Fig. 10A,a-d) (Boscia et al., 2012; 
Gopalakrishnan et al., 2013). For instance, NCX3 punctate 
immunoreactivity frequently overlapped with myelin rings surrounding 
axons. Quantitative analysis of colocalized points revealed that the co-
expression of these two proteins was significantly down-regulated at 
peak and chronic stages of EAE disease within demyelinated regions 
(Fig. 10B). This result was in line with the quantitative analysis of MBP 
fluorescence intensity. As shown in Figure 10C, a severe reduction of 
MBP during EAE progression was detected, being concentrated in 
plaque regions at the peak stage and with more disseminate 
appearance at chronic EAE stages (Fig. 10A, e-l). Quantitative confocal 
double immunofluorescence experiments of NCX3 with the axonal 
marker NF200 in spinal cord sections from control mice confirmed the 
presence of NCX3 exchanger within white matter axonal tracts. 
Quantification of colocalization studies within the range of 100 µm of 
distance from the slice border revealed a diverse amount of NCX3-
positive axons in the lateral, anterior and posterior tracts. In particular, 
NCX3 was highly represented in NF200 positive axons of the lateral 
and the anterior tracts, but very little colocalization was detected along 
the posterior tracts (Fig. 11A). 
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According to the literature, the loss of intensity of NF200 
immunoreactivity can be used as valuable marker to detect the axonal 
damage (Saatman et al., 1998; Yaghmai and Povlishock, 1992). 
Quantification analysis of NCX3 co-expression with the axonal marker 
NF200 within lateral tracts indicated that the number of NCX3-positive 
axons remained unchanged during the pre-onset stage (Fig. 11B; D,d-f)  
but they were significantly reduced during the peak stage (Fig. 11B; 
D,g-i)  and this reduction remained unchanged at the chronic stages 
(Fig. 11B; D,j-l). Interestingly, the number of NF200-positive axons 
detected at EAE peak and chronic stages was higher than those 
observed co-expressing also the NCX3 exchanger (Fig. 11C;B). 
Although confocal experiments revealed that the co-expression of 
NCX3 within demyelinated axons was progressively down-regulated 
during EAE course, the NCX3 immunosignal became progressively and 
intensely evident within regions of both MBP and NF200 loss. This 
effect was particularly evident at chronic stage where a large number of 
cells with oligodendroglia-like morphology surrounding damaged axons 
were observed (Fig. 11D, p-u). 
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A 
B C 
Figura 10. Co-expression of NCX3 with the myelin marker MBP in the white matter axonal tracts 
during EAE progression. (A) Confocal double-labelling experiments showing both NCX3 (red) and MBP 
(green) (a-l) in the white matter lateral tracts of control (a-d) and EAE affected-spinal cord during the Peak 
(e-h) and Chronic (i-l) stages. Scale bars: 50 µm (a-l) (B) Quantitative analysis of MBP/NCX3 colocalized 
points during EAE progression. The data were expressed as percentage of control. The values represent 
the means±S.E.M. (n=3-4). *P<0.05 versus control. (C) Quantitative analysis of MBP fluorescence intensity 
during the EAE clinical course. The data were expressed as percentage of control. The values represent 
the means±S.E.M. (n=3-4). *P<0.05 versus control. 
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Figura 11. Co-expression of NCX3 with the axonal marker NF200 in the white matter axonal tracts 
during EAE progression. (A) Quantification of the percentage of NCX3-positive axons in lateral, anterior 
and posterior tracts of control mice. Analysis were performed within the range of 100 µm of distance from 
the slice border. The values represent the means±S.E.M. (n=3-4). (B) Quantitative analysis of NCX3-
positive axons during EAE progression. The data were expressed as percentage of control. The values 
represent the means±S.E.M. (n=3-4). *P<0.05 versus control. (C) Quantitative analysis of NF200-positive 
axons during EAE progression. The data were expressed as percentage of control. The values represent 
the means±S.E.M. (n=3-4). *P<0.05 versus control. (D) Confocal double-labelling experiments showing 
both NCX3 (red) and NF200 (green) (a-u) immunosignal in the lateral (a-l) and posterior (m-u) tracts of 
control (a-c;m-o) and EAE-affected spinal cord at the Pre-Onset (d-f), Peak (g-i) and Chronic (j-l;p-u) 
stages. Scale bars: 20 µm (a-l); 50µm (m-r); 20µm (s-u).  
 
B 
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4. NCX3 co-expression with the oligodendrocyte lineage 
markers NG2, GalC and CNPase was up-regulated at EAE chronic 
stage  
 
To investigate whether NCX3 might be involved in the responses of 
oligodendroglial progenitors to EAE insult we performed colocalization 
experiments of NCX3 with anti-NG2, anti-GalC, and anti-CNPase 
antibodies at different time points during EAE progression.  
Confocal analysis revealed that NG2 immunosignal was strongly up-
regulated during the EAE course. In particular, at the pre-onset stage 
the anti-NG2 antibody sharply and intensely depicted positive cells with 
scattering distribution throughout the spinal cord (Fig.12A, b). At later 
time points, at peak and chronic stage of the disease, an intense 
expression of NG2 was observed within and around the demyelinated 
lesions (Fig.12A, c,d). Quantitative analysis revealed that the number of 
NG2-positive cells was significantly up-regulated during the EAE course 
when compared to control sections (Fig. 12B). Confocal double 
immunofluorescence experiments performed with anti-NCX3 and anti-
NG2 antibodies revealed that NCX3 was largely co-expressed with NG2 
in the white matter spinal cord of control animals (Fig. 12C, a-c). 
Quantification of NCX3-positive cells co-expressing NG2 within lateral 
tracts indicated that almost all NG2-positive cells co-expressed NCX3 at 
the pre-onset stage. By contrast, during the peak stage, although the 
number of NG2-positive cells was still significantly higher when 
compared to controls, the expression of NCX3 in these cells was 
reduced (Fig. 12D,B). Interestingly, a significant up-regulation of NCX3-
NG2 double-labeled cells was detected at the chronic stage. At this 
latter time point, almost all the NG2-positive cells co-expressed NCX3 
(Fig. 12C,j-l;D). 
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Confocally detected GalC immunoreactivity was strongly up-regulated 
and scattered detected along the lateral (Fig. 13A, a-d), anterior and 
posterior tracts (data not shown) during EAE course. Quantitative 
analysis revealed that the most significant increase in the number of 
GalC-positive cells was observed at the pre-onset stage. During the 
peak and the chronic stages the number of GalC-positive cells was 
reduced although significantly higher than those observed under control 
conditions (Fig. 13B). Confocal double immunofluorescence 
experiments performed with anti-NCX3 and anti-GalC antibodies 
revealed that several, although not all, GalC-positive cells co-expressed 
NCX3 in the white matter of control animals (Fig. 13C,a-c). 
Quantification of GalC-positive cells co-expressing NCX3 within lateral 
tracts indicated that almost all the GalC-positive cells co-expressed 
NCX3 at the pre-onset stage (Fig. 13C,d-f;D). By contrast, during the 
peak stage, although the number of GalC-positive cells was still 
significantly higher when compared to controls, the expression of NCX3 
in these cells remained at the basal level (Fig. 13B;D). Interestingly, a 
significant up-regulation of NCX3-GalC double-labeled cells was 
detected at the chronic stage. At this latter time points, almost all the 
GalC-positive cells co-expressed NCX3 (Fig. 13C,j-o,D).  
Confocal analysis performed with anti-CNPase antibody revealed that 
the number of CNPase-positive cells was significantly up-regulated only 
during the pre-onset and chronic stage of the disease (Fig. 14A,B). 
Interestingly, quantification of NCX3-CNPase double-labelled cells 
indicated that this isoform was intensely up-regulated in  CNPase-
positive cells both at pre-onset and chronic EAE stage (Fig. 14C,D). At 
this latter time point, NCX3 immunosignal was less intense expressed 
in the soma but much more evident along the processes of CNPase 
positive cells (14C,j-l). 
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Figure 12. Co-expression of NCX3 with the oligodendrocyte lineage marker NG2 in the white matter 
during EAE progression. (A) Confocal microscopic images showing NG2 (green) immunosignal in control 
(a) and in EAE affected-spinal cord at the Pre-onset (b), Peak (c) and Chronic (d) stages. Scale bars: 200 µm 
(a-d) (B) Quantitative analysis of NG2-positive cells during EAE progression. The data were expressed as 
percentage of control. The values represent the means±S.E.M. (n=3-4). *P<0.05 versus control. (C) Confocal 
double-labelling experiments showing both NCX3 (red) and NG2 (green) (a-l) immunosignal in the control (a-
c) and in EAE-affected spinal cord at the Pre-Onset (d-f), Peak (g-i) and Chronic (j-l) stages. Scale bars: 20µm 
(a-l). (D) Quantitative analysis of NCX3-NG2 double-labelled cells during EAE progression. The data were 
expressed as percentage of control. The values represent the means±S.E.M. (n=3-4). *P<0.05 versus control. 
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Figure 13. Co-expression of NCX3 with the oligodendrocyte lineage marker GalC in the white matter 
during EAE progression. (A) Confocal microscopic images showing GalC (green) immunosignal in control 
(a) and in EAE affected-spinal cord at the Pre-onset (b), Peak (c) and Chronic (d) stages. Scale bars: 200 
µm (a-d). (B) Quantitative analysis of GalC-positive cells during EAE progression. The data were expressed 
as percentage of control. The values represent the means±S.E.M. (n=3-4). *P<0.05 versus control. (C) 
Confocal double-labelling experiments showing both NCX3 (red) and GalC (green) (a-o) in the control (a-c) 
and in of EAE-affected spinal cord at the Pre-Onset (d-f), Peak (g-i) and Chronic (j-o) stages. Scale bars:50 
µm (a-l); 20 µm (m-o). (D) Quantitative analysis of NCX3-GalC double-labelled cells during EAE 
progression. The data were expressed as percentage of control. The values represent the means±S.E.M. 
(n=3-4). *P<0.05 versus control. 
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Figure 14. Co-expression of NCX3 with the oligodendrocyte lineage marker CNPase in the white 
matter during EAE progression. (A) Confocal microscopic images showing CNPase (green) 
immunosignal in control (a) and in EAE affected-spinal cord at the Pre-onset (b), Peak (c) and Chronic (d) 
stages. Scale bars: 200 µm (a-d). (B) Quantitative analysis of CNPase-positive cells during EAE 
progression. The data were expressed as percentage of control. The values represent the means±S.E.M. 
(n=3-4). *P<0.05 versus control. (C) Confocal double-labelling experiments showing both NCX3 (red) and 
CNPase (green) (a-l) in the control (a-c) and in EAE-affected spinal cord at the Pre-Onset (d-f), Peak (g-i) 
and Chronic (j-l) stages. Scale bars:50µm (a-c); 20µm (d-l). (D) Quantitative analysis of NCX3-CNPase 
double-labelled cells during EAE progression. The data were expressed as percentage of control. The 
values represent the means±S.E.M. (n=3-4). *P<0.05 versus control. 
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5. ncx3-/- mice exhibited increased susceptibility and impaired 
oligodendrocyte lineage responses to EAE disease  
 
To determine whether NCX3 might have a role in controlling neuronal or 
oligodendroglial responses under demyelinating conditions, the EAE 
disease was induced in ncx3 congenic wild-type (ncx3+/+), 
heterozygous (ncx3+/-) and knockout (ncx3-/-) female mice. In all these 
animal groups the clinical score was assessed until day 40 after 
immunization, when the mice were sacrificed and subjected to 
immunohistochemical experiments to analyze demyelination, axonal 
damage and oligodendroglial responses. 
Clinical assessment of EAE scores showed that both ncx3+/- and ncx3-
/- mice displayed an earlier onset of symptoms that occurred 4±0.8 and 
4±0.6 days after immunization respectively, when compared with their 
congenic wild-type littermates (10±0.5 dpi) (Fig. 15A,B). At the peak of 
the disease, the maximal severity of EAE was observed in ncx3+/- and 
ncx3-/- mice with a maximum clinical score of 4±0.3 and 4±0.5, 
respectively. During the chronic phase, until 40 dpi, ncx3+/- and ncx3-/- 
mice displayed higher level of disability when compared to ncx3 
congenic wild-type mice (Fig. 15A,B). By contrast, there was no 
differences in the disease progression between C57BL/6 control and 
wild-type congenic ncx3 mice (data not shown). Furthermore, neither 
ncx3+/+, or ncx3+/-, or ncx3-/- mice showed any clinical signs following 
CFA injection (data not shown).  
Ncx3-/- showed a dramatic reduction of intact myelin rings when 
compared to congenic wild-type at chronic stage. This was particular 
evident in white matter regions not affected by complete demyelination. 
In fact as showed in Figures 15C (a-d,l) the large majority of myelin 
rings observed in ncx3-/- sections appeared severely collapsed when 
compared to those observed in congenic animals. 
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Double labeling experiments performed with anti-MBP and anti-NF200 
antibodies on congenic ncx3+/+ and ncx3-/- spinal cord sections at 
chronic stage of the disease revealed a significant reduction in both 
MBP and NF200 immunoreactivity (Fig. 15C,e-j). In addition, 
quantitative analysis revealed that spinal cord axon diameters of EAE 
ncx3-/- mice were smaller than those of congenic, wild-type, ncx3+/+ 
mice (Fig. 15C,m).  
Quantitative immunohistochemical analysis of progenitor and 
premyelinating oligodendrocyte markers performed in both congenic 
and ncx3-/- mice at chronic stage indicated that a dramatic reduction of 
NG2-positive cells and CNPase-positive cells was observed in ncx3-/- 
mice if compared to congenic ncx3+/+ mice (Fig.16A;B). 
Confocal double immunofluorescence experiments performed with anti-
NG2 and anti-CNPase antibodies (Fig. 16C) revealed that several, 
although not all, NG2-positive cells co-expressed CNPase in the white 
matter of control animals. Interestingly, in ncx3-/- mice the 
NG2/CNPase co-expression was significantly down-regulated (Fig. 
16C,c). 
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Figure 15. Assessment of EAE clinical scoring, myelin ring and axonal diameter in ncx3+/+ and 
ncx3-/- mice at EAE chronic stage (A,B) Graph and table showing the patterns of EAE clinical symptoms 
in the MOG35-55-immunized ncx3 congenic wild-type (ncx3+/+), heterozygous (ncx3+/-) and knockout (ncx3-
/-) mice, respectively. Results represent average (mean±S.E.M.) of the data obtained from 4 animals per 
group in three indipendent experimental sessions. (C,a-d) Single immunohistochemical experiments 
performed with anti-MBP antibody in the spinal cord of ncx3+/+ (a,b) and ncx3-/- (c,d) mice at the EAE 
chronic stage. Scale bars: 20µm (a,c); 10 µm (b,d). (C,e-j) Confocal double-labelling showing MBP (red) 
and NF200 (green) co-expression in the spinal cord of ncx3+/+ (e-g) and ncx3-/- (h-j) mice at the EAE 
chronic stage. Scale bars: 10µm (e-j). (C,l,m) Quantitative analysis of intact myelin rings (l) and axon 
diameter (m) in the spinal cord of ncx3+/+ and ncx3-/- mice at the EAE chronic stage. The data were 
expressed as percentage of control (l). The value represent the means±S.E.M. *P<0.05 versus control. 
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Figure 16. Analysis of NG2 and CNPase expression in the spinal cord of  ncx3+/+ and in ncx3-/- 
mice at EAE chronic stage. (A,a-c) Single immunohistochemical experiments with anti-NG2 antibody 
performed in the spinal cord of ncx3+/+ (a,b) and ncx3-/- (c) mice at the EAE chronic stage. Scale bars: 
20µm (a,c); 5µm (b). (A,d) Quantitative analysis of NG2-positive cells in white matter spinal cord of 
ncx3+/+ and ncx3-/- mice at the EAE chronic stage. The data were expressed as percentage of control. 
The values represent the means±S.E.M. *P<0.05 versus control. (B,a-f) Single immunohistochemical 
experiments with anti-CNPase antibody performed in the spinal cord of ncx3+/+ (a-c) and ncx3-/- (d-f) 
mice at the EAE chronic stage. Scale bars: 20µm (a-f). (B,g) Quantitative analysis of CNPase-positive 
cells in white matter spinal cord of ncx3+/+ and ncx3-/- mice at the EAE chronic stage. The data were 
expressed as percentage of control. The values represent the means±S.E.M. *P<0.05 versus control.(C) 
Confocal double-labelling showing NG2 (red) and CNPase (green) co-expression in the spinal cord of 
ncx3+/+ (a,b) and ncx3-/- (c) mice at the EAE chronic stage. Scale bars:50µm (a,c); 10µm (b). 
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V. DISCUSSION 
The present study demonstrated that the Na+/Ca2+ exchanger NCX3 is 
involved in the oligodendroglial responses under demyelinating 
conditions. In addition, NCX3 knockout mice exposed to Experimental 
Autoimmune Encephalomyelitis showed an impaired oligodendrocyte 
lineage responses and worsening of clinical symptoms. 
Morphological analyses were performed at different time points during 
disease progression in order to assess inflammatory, neuronal and glial 
responses after MOG35-55-induced EAE. In line with previous studies, 
this insult reproduced the key pathological features of MS including: 
demyelination, axonal loss and glial activation (Trafreshi et al., 2005).  
Quantitative immunofluorescence experiments performed on EAE-
affected spinal cord revealed that the number of cells positive for the 
oligodendrocyte precursor cell (OPCs) marker NG2 as well as the 
premyelinating oligodendrocyte markers GalC and CNPase, were 
significantly up-regulated during the EAE clinical course. Although the 
MOG35-55-induced EAE might not be considered a model to study the 
remyelination process, many lines of evidence have shown that a 
common feature of experimental model of Multiple Sclerosis is the 
response of OPCs to repopulate the lesions site (Reynolds et al., 2002).  
Biochemical analysis performed on spinal cord tissue homogenates 
revealed that NCX3 protein levels were progressively up-regulated 
during EAE progression, and this effect was more significant at EAE 
chronic stage. In order to evaluate the involvement of the NCX3 isoform 
during EAE demyelinating conditions, in the current study we provided a 
clear picture of NCX3 expression and distribution within neurons and 
oligodendrocytes of the white matter spinal cord at different time points 
during EAE disease. Quantitative confocal double immunofluorescence 
experiments showed that, although the co-expression of NCX3 with 
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both the myelin protein marker MBP and the axonal marker NF200 was 
significantly down-regulated, the co-expression of NCX3 with the 
oligodendrocyte lineage markers, NG2,  GalC and CNPase was up-
regulated during EAE progression. These results suggested that NCX3 
isoform, by modulating Na+ and Ca2+ homeostasis, might be involved in 
oligodendroglial responses observed during EAE clinical course.  
Consistently with the possible role of NCX3 in OPCs responses, in a 
paper recently published by our research group, it has been 
demonstrated that calcium signaling mediated by NCX3 has a crucial 
role in the progression of OPCs into mature oligodendrocytes (Boscia et 
al., 2012).  
In support of our hypothesis we found that the response of OPCs cells, 
usually observed under demyelinating conditions, are compromised by 
the ablation of NCX3. In fact, analysis of NG2 and CNPase expression 
revealed that NCX3 knockout mice showed a reduced number of NG2- 
and CNPase-positive cells in the white matter spinal cord at the EAE 
chronic stage when compared to wild-type EAE-affected mice. 
Antibodies to the NG2 have proved exceedingly useful in following and 
quantitating the response of endogenous OPCs to demyelination 
(Reynolds et al., 2002). In addition, lines of evidence have shown that 
NG2-expressing OPCs responded to the inflammatory demyelination in 
MOG-induced EAE model by becoming reactive and increasing in 
number in a very focal manner. In accordance with our findings, 
evidence of NG2-positive OPCs in lesioned areas beginning to express 
the oligodendrocyte marker CNPase was also seen (Reynolds et al., 
2002). These observations further support our hypothesis indicating 
that, under demyelinating conditions, the NCX3 exchanger might have a 
relevant role in the stimulation of OPCs responses. 
Interestingly, the reduced recovery response observed in NCX3 
knockout mice at EAE chronic stage was accompanied by 
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morphological alterations of myelin and axons and by a worsening of 
clinical symptoms. In particular, in NCX3 knockout mice the amount of 
morphologically intact ring-like myelin structures was reduced when 
compared to NCX3 congenic wild-type mice at EAE chronic stage. This 
was particular evident in white matter regions not affected by complete 
demyelination; the large majority of myelin rings observed in NCX3 
knockout sections appeared severely collapsed when compared to 
those observed in congenic animals. In addition, NCX3 knockout mice 
exposed to EAE displayed a significant reduction of axonal diameter, 
this suggesting an increased axonal damage in EAE NCX3 knockout 
mice.  
It has been recently demonstrated that axonal degeneration contributes 
to the development of non-remitting neurological deficits and disability 
in Multiple Sclerosis, but the molecular mechanisms that underlie 
axonal loss in Multiple Sclerosis are not clearly understood. Although 
the Na+/Ca2+ exchanger appeared to be involved, its precise role in 
axonal degeneration has not been resolved. Waxam and co-workers 
(Craner et al., 2004a) have shown that NCX co-localizes with Nav1.6 in 
the injured axons in the spinal cord of mice with EAE (Craner et al., 
2004b). In particular, Craner et al. (2004a) have demonstrated the up-
regulated expression of Nav1.2 and Nav1.6 along extensive regions of 
demyelinated axons in EAE. Several lines of evidence suggest that 
Nav1.6 contributes to the persistent current that drives reverse NCX in 
injured axons in Multiple Sclerosis. The proposed mechanism involves 
massive sodium influx into axons that triggers reverse operation of the 
exchanger and subsequent influx of damaging levels of intra-axonal 
calcium that is associated with axonal injury (Craner et al., 2004a).  
Our results suggest that the NCX3 isoform might be not primarily 
involved in axonal degeneration. In fact, the findings of the present 
study revealed that the axonal expression of this exchanger isoform 
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was significantly reduced during EAE progression and, more 
importantly, NCX3 knockout mice displayed enhanced susceptibility to 
the disease and more severe neurological deficits. Further studies are, 
indeed, required to understand whether some other isoforms of the 
Na+/Ca2+ exchanger family might be involved. 
In addition, it is possible to speculate that the morphological alterations 
observed in myelin and axons of NCX3 knockout mice might be a direct 
consequence of the reduced oligodendroglial responses observed 
during the recovery phase. Consistently with the neuroprotective role of 
this exchanger, recent evidence point out to NCX3 isoform as a new 
potential therapeutic target for neuroprotection. Indeed, mice lacking 
NCX3 by silencing or transgenic approaches, show an enhanced 
cellular vulnerability to hypoxic-ischemic insults (Secondo et al., 2007) 
and a worsening of the infarct area after stroke (Pignataro et al., 2004; 
Molinaro et al., 2008). More recently, NCX3 has also been proposed as 
a new molecular effector involved in the neuroprotective effect of 
ischemic post-conditioning (Pignataro et al., 2011). In agreement with 
the beneficial role of this exchanger, it has been demonstrated that 
NCX3-deficient mice show skeletal muscle fiber necrosis and impaired 
neuromuscular transmission, which is clinically associated with reduced 
motor activity, weakness of forelimb muscles, and fatigability (Sokolow 
et al., 2004).  
Overall, our findings suggest that calcium signaling mediated by NCX3 
may be a key contributing factor to the impaired oligodendrocyte 
lineage responses that characterizes the EAE demyelinating condition. 
Further studies are needed to understand the role of NCX3 during 
remyelination processes. 
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